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ABSTRACT
The ret proto-oncogene encodes a membrane spanning 
glycoprotein which is a member of the receptor tyrosine kinase family 
(Hanks et al. 1988). RET is the signaling component of multi-subunit 
receptor complexes for the GDNF of family ligands, including GDNF, 
neurturin, artemin and persephin. The binding components of these 
receptor complexes are glycosyl-phosphatidylinositol (GPI)-membrane 
anchored molecules, known as GDNF family receptor a (GFRas). Four 
different GFRas (GFRal-4) dictate ligand specificity.
Germline point mutations of RET are responsible for the 
inheritance of MEN2 (Multiple Endocrine Neoplasia type 2) cancer 
syndromes which are usually divided into three different clinical 
subtypes: MEN2A, MEN2B and FMTC (familial medullary thyroid 
carcinoma), which are all autosomal dominant cancer syndromes. 
Inactivating mutations of RET cause an impaired development of the 
enteric nervous system which is responsible for the Congenital 
megacolon or Hirschprung's disease (HSCR).
The aim of my work was to study the expression of different RET 
mutants In order to highlight their biological role in diverse cellular 
context. In particular, we focused on gain of function cysteine 
mutations that are responsible for medullary thyroid carcinoma (MTC) 
by causing covalent RET dimérisation, leading to ligand-independent 
activation of its tyrosine kinase. In this context, the association of
Abstract
Cys®°® and Cys®^ ° activating mutations with HSCR is still an unresolved 
paradox. To address this issue, we have developed a transgenic model 
for human diseases (specifically. Multiple Endocrine Neoplasia type 2 
and Hirschsprung disease) through the insertion of a gain and loss of 
function RET mutation, the RET^ z^oR jp mouse genome. We have 
also studied the in vitro effects of a tyrosine kinase Inhibitor PPl, 
which we propose could represent a potential treatment strategy and 
merits further testing, using in vivo models such as the one we have 
generated.
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1. REVIEW OF THE LITERATURE
1.1 RET PROTO-ONCOGENE AND ITS PHYSIOLOGICAL FUNCTIONS
1.1.1 Identification of RET as an oncogene
The ret proto-oncogene encodes a membrane spanning 
glycoprotein which is a member of the receptor tyrosine kinase family 
(Hanks et al. 1988). I t  was first identified as a component of a 
chimeric oncogene when DNA from lymphomas, colon and gastric 
tumours produced transformation of NIH3T3 cells (Takahashi et al, 
1985). These rearrangements were an artefact of the transfection 
assay. The chimeric protein comprised an N-terminal region with a 
motif for dimerization fused to a new tyrosine kinase domain that 
afterwards was found to belong to a transmembrane receptor named 
RET (REaranged during Transfection) (Takahashi et al, 1988).
The RET gene lies on chromosome band lO q ll.2  and comprises 
21 exons spanning 55kb. The gene encodes a protein similar to other 
TK receptors (Ishizaka et al, 1989). Homologues of RET have been 
identified in higher and lower vertebrates, as well as in Drosophila 
Melanogaster (Hahn and Bishop, 2001).
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1.1.2 Structure and function of the RET receptor tyrosine kinase
RET protein is characterized by an N-terminal signal peptide, a 
cadherin-like motif and a cysteine rich region in the extracellular 
domain, a transmembrane domain and the intracellular domain that 
contains the tyrosine kinase domain interrupted by 27 amino acid of 
the kinase insert (Itoh et al, 1992; Schneider, 1992). Its structure is 
similar to the ones of other tyrosine kinase receptors, apart from the 
presence of the cadherin domain (Schneider, 1992). Cadherins are 
Ca^'^-dependent cell-cell adhesion proteins and their adhesive property 
depends on a domain of 110 amino acids, repeated in tandem, in the 
extracellular region. The binding of calcium between each cadherin 
domain is believed to induce linearization and strengthening of the 
whole extracellular region, thus protecting cadherins from proteolytic 
degradation. Multiple sequence alignments and computer modelling 
analyses have revealed that the extracellular domain of RET comprises 
four repeated cadherin-like domains (Anders et al, 2001). In addition, 
it has been demonstrated that the extracytoplasmic domain of RET 
binds specifically to Ca^^ ions, thus confirm the association of RET with 
the cadherin super family. Remarkably RET does not fold correctly 
inside the endoplasmic reticulum when extracellular calcium is 
depleted (van Wearing et al, 1998), and binding of ligands is calcium- 
dependent (Nozaki et al, 1998). Together, these data suggest tha t the
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fixation of calcium through the cadherin domains of RET induces, or 
stabilizes, a conformational change in the extracytoplasmic domain, 
which is necessary for the interaction with its cognate ligands.
RET is expressed as either a ISOkDa or a 170kDa protein, 
respectively corresponding to the immature incompletely glycosylated 
form present in the endoplasmic reticulum and to the mature RET 
protein, fully glycosylated and expressed at the cell surface (Taniguchi 
et al, 1991). The C-terminal tail, starting from aa 1062, shows three 
different splicing variants: the long isoform of 1114 aa (Iso51), the 
middle isoform of 1106 aa (iso 43) and the short isoform of 1072 aa 
(iso9) (Tahira et al, 1990; Myers et al, 1995).
In situ hybridization showed that RET is present in peripheral 
enteric, sympathetic and sensory neurons. RET staining is also 
observed in central motor, dopamine and noradrenalin neurons 
localized in the ventral half of the spinal cord, in the neuroretina and in 
the olfactory epithelium (Pachnis et al, 1993; Attie-Bitach et al, 1998; 
Manie et al, 2001). In these locations RET activation can promote 
neuronal cell survival and differentiation. Outside the nervous system, 
RET is involved in renal ontogenesis, in particuiar in mesonephric duct 
and branching ureteric bud development, where a chemotactic role for 
GDNF has been demonstrated (Taraviras and Pachnis, 1999) although 
RET transcripts disappear after birth. All these observations are
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supported by studies on RET- and coreceptor-null mice, or on 
transgenic mice with a defective RET TK domain that show severe 
defects of the innervation of the hindgut and branching of the ureteric 
bud (Airaksinen et al, 1999; Baloh et al, 2000).
1.1.3 Different splice isoforms of RET
In mammals, c-RET is alternatively spliced to produce at least 
two major isoforms, RET9 and RET51, that differ only in the amino 
acid sequence of the C-terminal tail. The two RET isoforms are highly 
conserved between species, suggesting that these regions have 
important functions that are conserved in evolution. Although the two 
Isoforms behave similarly in a number of in vitro assays, several 
observations have suggested that they have different and tissue- 
specific effects on embryogenesis and tumorigenesis. Monoisoformic 
mouse strains expressing only RET9 or RET51 in place of the normal 
complement of c-Ret gene products, demonstrated that signaling by 
RET9 is critically important for kidney morphogenesis and enteric 
nervous system development and postnatal life: signaling by RET51 
alone, in the absence of RET9 resulted in characteristic defects in the 
development of the excretory and enteric nervous systems (de Graaff 
et al, 2001) indicating that RET51 is dispensable during 
embryogenesis. Furthermore, transgenic overexpression of RET51 only
Ca
Tm
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isoform/RETSl)
Figurel. RET structure
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partially compensates for the loss of RET9 in kidney and enteric 
nervous system development. RET51, but not RET9, is required for the 
metabolism and growth of mature sympathetic neurons (Tsui-Pierchala 
et al, 2002b). Moreover, Tsui-Pierchala et al (Tsui-Pierchala et al, 
2002a) provided evidence that RET9 and RET51 are not only 
functionally distinct, but also activate a distinct assortment of signaling 
pathways in neurons and are not able to associate with each other 
after GDNF stimulation probably due to different subcellular 
localization of the two isoforms. The alternative splicing of RET might 
account for an evoiutionarily conserved mechanism to expand the 
number of activities regulated by a RTK.
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1.1.4 Identification of ligands and co-receptors for RET
The RET ligand was unknown until 1996 when the Glial Derived 
Neurotrophic Factor (GDNF) was discovered (Trupp et al, 1996; 
Durbec et al, 1996). The first member of the GDNF family was 
identified due to the ability of conditioned media, from glial cell line 
culture, to promote the survival of dopaminergic neurones. Mice null 
for GDNF were found to display a very similar phenotype to Ret-null 
mice, in terms of renal agenesis, colon aganglionosis and absence of 
superior cervical ganglia. GDNF was also shown to cause RET 
phosphorylation and exert trophic effects on RET-expressing tissue 
explants (Sanchez et al, 1996; Pichel et al, 1996; Moore et al, 1996; 
Trupp et al, 1996). Nevertheless, no direct interaction of RET and 
GDNF could be demonstrated and a co-receptor was subsequently 
identified as being necessary for GDNF mediated activation of RET 
(Jing et al, 1996; Sanicola et al, 1997). GDNF was the firs t of a fam ily 
of 4 ligands (to date) comprising Neurturin (NTN) (Kotzbauer et al, 
1996), Persephin (PSP) (Milbrandt et al, 1998) and Artemin (Baloh et 
al, 1998b; Baloh et al, 1997; Sanicola et al, 1997; Jing et al, 1997). 
They represent a new subclass of the transforming growth factor TGFp 
superfamily and like members of this family, glial-cell-line-derived 
neurotrophic factor iigands are secreted as disulphide-linked dimers
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that contain three disulphide bonds arranged in a typical configuration 
known as "cysteine knot" (Eigenbrot et al, 1997). All these factors are 
structurally closely related, sharing 40% identity at the amino acid 
level. Similar to neurotrophins, the GDNF family of ligands are also 
firstly synthesized as precursor polypeptides that are processed to 
mature proteins and then secreted (Lin et al, 1993).
GDNF was described originally as a trophic factor for 
dopaminergic neurons (Lin et al, 1993), although now it seems to be 
involved in the survival of a wide spectrum of neurons, including 
motor, noradrenergic, enteric, parasympathetic, sympathetic and 
sensory neurons (Airaksinen et al, 1999; Baloh et al, 2000). NTN, 
ARTN and PSPn share similar neurotrophic effects to GDNFs although 
PSPN does not support the survival of peripheral neurons (Airaksinen 
et al, 1999; Baloh et al, 2000).
RET signal starts from a multimeric complex composed of the 
RET kinase and any one of four different high-affinity glycosyl- 
phosphatidylinositol (GPI)-linked coreceptors, designated as GFRa
1,2,3 and 4 (Jing et al, 1996; Treanor et al, 1996; Klein et al, 1997; 
Buj-Bello et al, 1997; Baloh et al, 1997; Jing et al, 1997; Baloh et al, 
1998a; Enokido et al, 1998;Thompson et al, 1998). They define a 
structurally related subfamily, although alternatively spliced forms of 
GFRa-4 have been predicted to encode transmembrane and soluble
10
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isoforms (Lindahl et al, 2000; Masure et al, 2000). The interactions 
between the identified ligands and coreceptor proteins have been 
assayed using different methods such as the equilibrium binding of 
radiolabeled ligands to coreceptors, the ability to promote survival of 
neurons microinjected with each of the coreceptors and the ability to 
induce RET autophosphorylation. I t  has been demonstrated that the 
four RET ligands GDNF, NTN, PSP and Artemin interact preferentially 
with GFRa 1, 2, 3 and 4 respectively (Creedon et al, 1997;Baloh et al, 
1997;Sanicola et al, 1997;Jing et al, 1997). Nevertheless, equilibrium 
binding data suggest that a low affinity interaction was also possible 
and that there was a degree of cross-talk between ligands and 
coreceptors (Baloh et al 1997, Jing et al 1997, reviewed by Saarma 
2000), except that mammalian GFRa-4 coreceptor binds only PSPN 
(Lindahl et al, 2001).
A. Glial Derived Neurotrophic Factor (GDNFJ
Transcription of the gene usually produces a full-length GDNF 
mRNA of 4.5kb, but a 6.0 kb transcript mRNA has also been observed 
and encodes a 211 amino acid precursor polypeptide, from which the 
mature protein of 134 amino acids is produced by proteolytic cleavage 
(Lin et al, 1993). There are two potential glycosylation sites in the 
mature protein, which has a Mr of 18 to 22 kDa (Lin et al, 1993).
11
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GDNF promotes the survival of several types of neurons in both the 
central and peripheral nervous systems. Exogenous GDNF can 
maintain dopaminergic, noradrenergic and motor neurones of the 
central nervous system (Lin et al, 1993; Henderson et al, 1994; 
Arenas et al, 1995; Messer et al, 2000; Rosenblad et al, 2000), as well 
a various sub-populations of peripheral sensory and sympathetic 
neurones (Henderson et al, 1994; Buj-Bello et al, 1995; Ebendal et al, 
1995; Trupp et al, 1995; Arce et al; 1998). The pharmacological 
effects of GDNF on midbrain dopaminergic neurones have been studied 
and GDNF is considered a potential drug candidate for the treatment of 
Parkinson's disease, (reviewed by Lapchak et al, 1997; Grondin et al, 
1998).
Transgenic models have demonstrated that the development of 
dopaminergic neurones in GDNF-deficient embryos is normal. 
However, homozygous mice die at birth before the maturation of 
dopaminergic nervous system. GDNF-deficient mice show a 20%-30% 
reduction in the number of moto neurones in the trigeminal ganglia 
and the spinal cord (Moore et al, 1996; Sanchez et al, 1996). 
Transgenic mice over expressing GDNF under a muscle-specific 
myogenic promoter show hyper innervations of neuromuscular 
junctions for several weeks after birth (Nguyen et al, 1998),
12
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suggesting that GDNF also functions as a muscle-derived factor for 
motor axon branching and synapse elimination.
Outside the nervous system, GDNF mRNA is abundantly 
expressed in condensing nephrogenic mesenchyme cells around the 
tips of the invading ureteric buds, while branching bud tips express the 
functional receptor RET (Pachnis et al, 1993; Widenfalk et al, 1997). 
The specific expression pattern of GDNF and RET suggested a crucial 
paracrine regulatory role of GDNF in kidney morphogenesis. GDNF- 
deficient mice lack kidneys and die in the firs t postnatal day (Moore et 
al, 1996; Pichel et al, 1996).
GDNF increases motility, dissociation of cell adhesion and migration of 
the RET-transfected Madin-Darby canine kidney (MDCK) cell line 
toward a localised source of GDNF (Tang et al, 1998) and promotes 
scattering of the RET-transfected human neuroectodermic SK-N-MC 
cell line.
B. Neurturin (NRTN)
NTRN, with 42% similarity to GDNF at the amino acid level, was 
identified on the basis of its ability to support the survival of 
sympathetic postganglionic neurones in culture (Kotzbauer et al, 
1996). NRTN promotes the survival of several populations of neurones 
in both the central and peripheral nervous systems (Klein et al, 1997).
13
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There is a difference between the effect of GDNF and NRTN on 
developing and adult substantia nigra dopaminergic neurones; GDNF 
has wider survival, neuritogenetic and hypertrophic effects when 
compared to the selective survival-promoting effects of NRTN (Akerud 
et al, 1999; Rosenblad et al, 1999a,b). NRTN affects parasympathetic 
neuronal survival and targets innervations. NRTN-deficient mice have 
a strikingly similar phenotype to mice lacking GFRa2, showing defects 
in the parasympathetic enteric nervous system (Rossi et al, 1999). 
They are viable and fertile, but have a dramatically reduced myenteric 
plexus innervation. NRTN and GFRa2 together with RET, regulate the 
parasympathetic innervation of the penis and may also have a role in 
the regulation of heart innervation (Laurikainen et al, 2000, Hiltunen 
et al, 2000).
ÔDNF NRTN ART PSP
1(u  II ' <6FRa2 z6FRn3 ôFRnt4
RET
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Figure 2. The binding of GDNF fam iiy ligands and receptors. RET
Is the signaling component of multisubunit receptor complexes for the 
GDNF family ligands that includes GDNF, neurturin, artemin and 
persephin. The binding components of these receptor complexes are 
glycosyl-phosphatidylinositol (GPI)-membrane anchored molecules, 
known as GDNF family receptor a (GFRas). Four different GFRas 
(GFRal-4) dictate the ligand specificity of the complex. The solid 
arrows represent the functional binding that activates RET most 
potently, whereas the dotted arrows indicate weak interactions with 
receptor.
1.1.5 Recruitment of RET to lipid rafts and action of GDNF
Lipid rafts are sphingolipid- and cholesterol-rich membrane 
domains thought to act as scaffolding centres which mediate the 
assembly of a specific set of signal transducers (Tansey et al, 2000). 
In fact, raft micro domains might help to compartmentalise sets of 
signaling molecule at both sides of the plasma membrane, allowing 
them to interact with each other in a regulated manner, and at the 
same time preventing them from interacting with proteins excluded 
from rafts (Simons and Toomre 2000). I t  was demonstrated that 
inactive RET is localised outside rafts (Paratcha et al, 2001, reviewed
15
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by Saarma 2001). Glycosyl phosphatidylinositol-anchored molecules 
are known to be located within lipid rafts and, consistent with this, 
GFRa-1 recruits RET to lipid rafts upon treatment with GDNF (Tansey 
et ai, 2000). Moreover, depletion of cholesterol with methyi-p- 
cyciodextrin causes disruption of the raft structure and decreases 
GDNF signalling, indicating that compartmentaiization of RET and 
GFRa-1 in lipid rafts is crucial for transduction of the GDNF signal. I t  is 
therefore possible that even the other GFRa proteins are able to 
recruit RET into lipid rafts.
1.1.6 RET activation
Current experimental data favour the existence of two models 
for the activation of RET, including in as signalling and In trans 
signalling mechanisms. Originally the proposed model for RET 
activation states that the ligand-receptor complex is assembled in a 
step-wise fashion (Jing et al, 1996). A dimeric GDNF molecule induces 
or stabilizes the formation of a complex with two monomers of GFRal. 
In a second step, this complex contacts two molecules of RET and 
promotes their homodimerization and autophosphorylation at tyrosine 
residues (in cis signalling) (Paratcha et al 2001 and reviewed by
16
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Saarma 2001). GFRal recruits RET to lipid rafts only following GDNF 
stimulation, resulting in the association of RET and Src. The 
overlapping and complementary expression of GFRas with each other, 
with ligands and with RET, suggests that the functions of the GDNF 
family can be regulated in various ways. GFRal is widely expressed in 
the absence of RET, suggesting alternative roles for "ectopic" sites of 
GFRal expression. GFRal also binds its ligand and activates RET when 
provided exogenously in soluble form or immobilised on agarose beads 
(Treanor et al, 1996; Yu et al, 1998; Qiao et al, 1999). GFRas are 
usually bound to the plasma membrane but a specific cleavage by a 
putative phospholipase or protease produces soluble forms of these 
co-receptors (Paratcha et al, 2001). Thus, another possibility is that 
GFRal may also function in a non-cell-autonomous manner to capture 
and concentrate diffusible GDNF family ligands from the extracellular 
space and then present these factors in trans to affect RET-expressIng 
cells {in trans signalling) (Paratcha et al, 2001; Saarma et al, 2001). 
Activation of RET in trans also results in the mobilisation of RET to lipid 
raft membranes even in cells that lack endogenous GPI-anchored 
GFRal (Paratcha et al, 2001). Upon activation in cis, RET is recruited 
to membrane rafts by a rapid extracellular mechanism, most likely 
driven by its affinity for newly formed GDNF/GFRal complexes, 
independently of its tyrosine kinase activity. In contrast, recruitment in
17
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trans is delayed, sustained, and requires an active RET tyrosine 
kinase, suggesting the involvement of intracellular events (Paratcha et 
al, 2001). Downstream signalling after stimulation in trans is at least 
as efficient as that induced in cis and potentiates downstream 
signalling, neuronal survival and differentiation (Paratcha et al, 2001). 
Based on the existing data it is possible to assume that also other 
members of the GDNF family, Neurturin, Artemin and Persephin 
interact with their cognate co-receptor and activate RET similarly to 
GDNF.
18
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Figure 3. Possible mechanisms of RET activation, a) cis signaling: 
GFRal recruits RET to lipid rafts, after treatment with GDNF (tyrosine 
kinase independent process), b) trans signaling: GDNF binds to soluble 
GFRal and the GDNF- GFRal complex triggers RET activation Trans
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activated RET is located both outside and in the lipid compartment 
(tyrosine kinase dependent process).
Intracellular signaling through RET has been extensively studied 
(reviewed by Airaksinen et al, 1999; Takahashi 2001). Since RET 
ligands were unknown until 1996, extensive studies on RET signalling 
have been performed using chimeric or oncogenic version of the 
transmembrane RET, that display constitutive tyrosine kinase activity. 
In fact the activation of the signalling cascade starts upon ligand 
binding that induces receptor autophosphorylation and consequent the 
phosphorylation of tyrosine residues. RET can activate various 
signaling pathways including RAS/extra cellular signal-regulated kinase 
(ERK), phosphatidylinositol 3 kinase (PI3K)/AKT, p38 mitogen 
activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) 
pathways (Airaksinen et al, 1999; Trupp et al, 1999; Hayashi et al,
2000). These signals are transmitted through phosphotyrosines 
present in the Intracellular domains of RET that mediate specific 
binding to various scaffolding, anchoring, adaptor proteins and 
enzymes that posses Src homology-2 (SH2) or protein tyrosine- 
binding (PTB) domains. The RET C-terminal tail comprises five 
different phospho-tyrosine residues (Y687, Y826, Y1015, Y1029 and
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Y1062) apart from the TK. In addition, the long isoform displays two 
extra tyrosine residues: Y1090 and Y1096; the latter is phosphorylated 
in RET/2A but not in RET/2B (Liu et al, 1996). In particular, Y1062 is a 
multidocking site interacting with a number of transduction molecules: 
SHC, FRS2, IR S l/2 , DOK proteins (Arighi et al, 1997; Kurokawa et al,
2001) and Enigma (Durick et al, 1998) and has a critical role in 
signaling initiation during embryogenesis and tumorigenesis (reviewed 
by Hayashi et al, 2000; Takahashi 2001). All the RAS/ERK, PI3K/AKT, 
p38MAPK and JNK pathways are activated mainly through tyrosine 
1062 that is the binding site for SHC adaptor proteins. After binding of 
SHC to tyrosine 1062, SHC further associates with GABl/2 adaptor 
proteins and the GRB2/S0S complex, leading to the activation of 
PI3K/AKT and RAS/ERK signaling pathways, respectively. SNT/FRS2 is 
a lipid anchored docking protein with a phosphotyrosine-binding (PTB) 
domain, and it may be involved mainly in activation of the RAS/ERK 
signaling pathway. The p38MAPK, JNK pathways are also activated 
through tyrosine 1062. Moreover, RET signals also through PLCy, that 
binds Y1015 (Borrello et al, 1996) and through GRB2 that binds only 
the long isoform at Y1096 (Alberti et al, 1998)
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Figure 4. RET signaling pathways. Activation of RET leads to 
autophosphorylation of tyrosine residues (Y-P) within the cytoplasmic 
tail, creating docking sites for multiples signaling partners.
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1.2 RET IN HUMAN PATHOLOGIES
1.2.1 RET oncogenes in papillary thyroid cancer
Chromosomal rearrangements producing chimeric oncogenes are 
frequently associated with human cancer. Several lines of evidence 
suggest that they are involved in the pathogenesis of tumors. Among 
solid tumors, papillary thyroid carcinoma (PTC) provides a unique 
model of a frequent generation of chimeric oncogenes through 
chromosomal rearrangements. Transfection of DNA from papillary 
thyroid carcinomas into NIH3T3 cells led to the identification of 
rearrangements of RET tyrosine kinase receptor with foreign 
sequences. In fact, PTCs are characterized by the generation of fusion 
proteins, made of the N-terminus derived from different partners and 
the C-terminus of one of the two receptors, carrying a cytoplasmic 
tyrosine kinase domain.
In 1987, Dr. Pierotti's group in Milan, in collaboration with the 
group headed by G Vecchio and A Fusco of the University of Naples, 
isolated the first activated version of the RET oncogene, named 
RET/PTC (Papillary Thyroid Cancer) (Fusco et al, 1987). Afterwards, a 
number of different RET/PTCs have been isolated, where RET TK 
domain was found fused with different partner genes.
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A. RET/PTCl
RET/PTCl originates from an inversion of chromosome 10, 
inv(10 )(q ll.2q21 .2 ), and results from the fusion of the RET-TK 
domain and H4 (D10S170) gene, whose function is still unknown. The 
H4/RET fusion incorporates 101 amino acids of H4, predicted to 
encode a leucine zipper domain responsible for RET/PTCl 
oligomerization and constitutive tyrosine kinase activity (Tong et al,
1997). A novel rearrangement containing the N-terminal 150 residues 
of H4 creates an oncoprotein named RET/PTClL able to transform 
NIH3T3 cells with 5-fold lower efficiency than RET/PTCl. Its low 
transforming ability may be one of the reasons explaining its low 
frequency in human thyroid carcinomas (Giannini et al, 2000). 
Recently H4 has been found fused to the platelet-derived growth factor 
receptor beta gene in atypical chronic myeloid leukemia (t(5 ; 
10)(q33;q22) (Schwaller et al, 2001). Interestingly RET/PTCl 
rearrangement has been found associated with post-Chernobyl PTC of 
long latency.
B. RET/PTC2
In RET/PTC2, RET-TK is fused to the type I alpha regulatory 
subunit of protein kinase A (RI alpha) and is generated by a reciprocal
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and balanced chromosome translocation (Lanzi et al, 1992; 
Bongarzone et al, 1993). The resulting 596-aa protein contains the 
first two-thirds of RIa. The wild-type RI% subunit dimerizes in an 
antiparallel orientation between Cys-16 and Cys-37 (Bubis et al, 
1987). RET/PTC2 deletion mutants showed that the Rl^dimerization 
domain is the only portion of RIk required for RET/PTC2 mitogenic 
activity, thus suggesting that RET TK is activated in RET/PTC2 via the 
dimerization domain of Rio (Durick et al, 1995).
C. RET/PTC3
Both RET/PTC3 and RET/PTC4 oncogenes are generated by an 
intrachomosomal rearrangement with the ELEla/ARA70 gene. 
RET/PTC3 contains the first 238 amino acids of the androgen receptor- 
associated protein 70 (Santoro et al, 1994). Bongarzone et al. 
(Bongarzone et al, 1997) identified a short homology sequence (3 to 7 
bp) in the two rearranging genes and a break cluster region (bcr) in 
ELEl, in A+T rich regions (Bongarzone et al, 1997).
The N-terminal coiled-coil domain of ELEla/ARA70 mediates 
oligomerization, RET kinase activation and transforming ability. In fact, 
expression of RET/PTC3 mutants lacking the N-terminal coiled-coil 
domain does not lead to foci formation in NIH3T3 cells. Moreover, the 
same domain mediates the interaction between RET/PTC3 and ELEla
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/ARA70, causing oncoprotein re-localization to the plasma membrane 
(Monaco et al, 2001). Intrachromosomal rearrangements involving 
RET and the adjacent H4 or ELElc/ARA70 gene on chromosome 10 are 
very frequent events in thyroid cancer of children from the Chernobyl- 
contaminated zone (58%) (Klugbauer et al, 1995; Nikiforov et al,
1997). In addition, RET/PTC3 rearrangement is strongly associated 
with PTC of short latency and connected with a solid-follicular variant 
of PTC (Thomas et al, 1999). Consistent with this, mice carrying 
RET/PTC3 display an aggressive tumor phenotype, including 
competence for lymph node métastasés (Powell et al, 1998). In 
contrast, RET/PTCl transgenic mice develop follicular hyperplasia and 
carcinoma, but not invasive cancer (Santoro et al, 1996). In RET/PTC3 
transgenic mice thyroids, a high frequency of solid-type papillary 
carcinomas was found, similarly to what was observed in thyroids of 
PTC3 positive patients from the Chernobyl-contaminated area. This 
suggests that the RET/PTC3 gene is critical for the development of the 
solid subtype of papillary thyroid cancer. Recently, Basolo et al 
associated the RET/PTC3 rearrangement also with the Toll-Cell Variant 
of papillary thyroid carcinoma. The finding that RET/PTC3 is present in 
aggressive histological PTC subtypes (Solid PTC and TCV) could 
depend on a more efficient in vitro mitogenic ability and MAPK
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activation of this RET rearrangement in comparison to RET/PTCl 
(Basolo et al, 2002).
D. RET/PTC4
In the case of RET/PTC4, despite the presence of the same 
RET/PTC3 breakpoint in exon 5 of the ELEla/ARA70 gene, the 
sequence of the rearranged genomic DNA showed a different intra- 
exonic breakpoint in the RET proto-oncogene. Moreover, it has been 
demonstrated that exon 5 of ELElo/ARA70 is joined to exon 11 
instead of exon 12 of the RET gene. As a consequence, the RET/PTC4 
cDNA sequence is 93 nucleotides longer than that of RET/PTC3 
(Fugazzola et al, 1996).
E. Other PTCs
After the Chernobyl power plant explosion, an unusual number 
of thyroid cancers was noted in Belarus and Ukraine, between 10 to 30 
fold higher than in the rest of Europe. The analysis of PTCs derived 
from the contaminated zones led to the identification of other 
rearranged forms of RET, where RET-TK was fused to 7 different donor 
genes. For instance, the RET/PTC5 fusion partner protein is G0LGA5, a 
coiled-coil protein expressed on the Golgi surface (Klugbauer et al,
1998). RET/PTC6 and RET/PTC7 respectively display rearrangements
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with the Transcriptional Intermediary Factor 1-Alpha and Gamma 
(Klugbauer and Rabes, 1999). This protein family is able to bind to the 
ligand-dependent activation function (AF2)-activating domain of the 
estrogen receptor, RARs, RXRs, the vitamin D3 receptor and regulate 
transcription. Kinectin is the RET/PTC8 partner (Salassidis et al, 2000), 
whereas Rfg9, a putative cytoplasmic protein that might be involved in 
intracellular transport processes, is rearranged with RET to form 
RET/PTC9 (Klugbauer et al, 2000). In RET/PCM-1 the activating 
sequences belong to a gene coding for a centrosomal protein that 
displays distinct cell cycle distribution (Corvi et al, 2000). The last RET 
rearrangement found is ELKS/RET. ELKS mRNA is ubiquitously 
expressed, with the highest expression in heart, placenta, pancreas, 
thyroid and testis, but the function of the ELKS protein is still unknown 
(Nakata et al, 1999).
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ONCOGENE ACTIVATING
GENE
ACTIVATING GENE 
FUNCTION
CHROMOSOME
PTCl* H4/D10S170 Unknown 10q21
PTC2 RI pt(PKA) PKA regulatory subunit 17q23-q24
PTC3*-
PTC4*
ELEl Androgen receptor-associated 
protein (co-transcription factor)
lO q ll.2
PTC5* G0LGA5 Golgi auto antigen 14q
PTC6* hTIFla Transcription intermediary 
factor
7q32-q34
PTC7* hUFl Y RFG7 Transcription intermediary 
factor
lp l3
PTC8* Kinectin Vesicle membrane anchored 
protein
14q22.1
PTC9* RFG9 Putative Intracellular transport 
protein
18q21-22
RET/PCMl PCMl Centrosomal protein 8p22-p21.3
Elks-RET ELKS Unknown 12pl3
* from patient exposed to Chernobyl radiations 
Table 1 -  RET oncogenes in papillary thyroid carcinomas
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1.2.1.1 RET rearrangements as a common event
There are some common features that gather all RET fusion 
partner proteins. They are ubiquitously expressed, display cytoplasmic 
localization and contain different protein-protein interaction motifs. 
Coiled-coil domains often represent the dimerization/oligomerizaton 
domains present in the activating genes (Lupas et al, 1991; Lupas, 
1996). Moreover, all the rearranged oncoproteins are able to self­
associate, thanks to the oligomerization domain, and this triggers the 
constitutive trans-autophosphorylation of the tyrosine kinase domain, 
thus mimicking receptor dimerizaton upon ligand binding. The 
importance of promoting an oligomerization, which in turn leads to 
constitutive activation, has been demonstrated in several cases 
involving different oncogenes (ie RET/PTCl, RET/PTC2, RET/PTC3, 
TRK-T3, and also TPR/MET, Bcr/AbI, PLM/RAR) (Tong et al, 1997; 
Durick et al, 1995; Monaco et al 2001; Greco et al 1998; Rodrigues 
and Park, 1993; McWhirter et al, 1993; Grignani et al, 1999). Another 
common feature of these oncoproteins is a different sub cellular 
localisation with respect to the wild type receptors, which 
physiologically work on the cell surface. The chimeras are localised in 
the cytosol and this sub-localisation could be driven by the activating 
portion. In the case of RET/PTC2, different localization was observed 
for the two isoforms (Borrello et al, 2002). Finally, rearrangements
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lead to the ectopic expression of kinases in epithelial follicular cells, 
although it has been recently demonstrated that RET could be 
physiologically active also in thyrocytes (Bunone et al, 2000).
All the chromosomal rearrangements are balanced reciprocal 
events. The rearrangements involve one of the two alleles of the 
activating gene. The non-rearranged allele is still present but the 
encoded protein could have a different sub cellular localization or its 
expression level could be decreased, as demonstrated for RET/PCMl 
(Corvi et al, 2000). This could be either due to allelic inactivation or to 
the coexistence of wild type and rearranged forms that could affect 
protein function or stability. The haploinsufficency could be directly 
responsible for tumorigenesis if the proteins involved in the oncogene 
activation are important for physiological cell activity (RI alpha for 
RET/PTC2).
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Figure 5. Mechanisms of chromosomal rearrangem ents  
generating fusion transforming genes. RET thyroid oncogenes
These rearrangements cause the fusion of the RET tyrosine kinase 
encoding domain to the 5'-terminal domain of heterologous genes, 
such generating RET/PTC oncogenes. Common features of genes
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activating RET: ubiquitous expression, cytoplasmic localization,
presence of coiled-coil domains promoting dimerization Activating 
genes are indicated; SP: signal peptide; TM: transmembrane domain; 
TK: tyrosine kinase domain; C: coiled -coil domain.
1.2.1.2 Clinical features of PTC expressing RET oncogenes
Analysis of clinical characteristics of sporadic and radiation- 
induced papillary thyroid tumors indicates the existence of a 
correlation between RET positivity and young age of patients. In fact it 
has been reported that in papillary thyroid neoplasias, the frequency of 
RET activation is significantly higher in patients under the age of 30 
(Bongarzone et al, 1996). In addition, children are much more 
sensitive to the tumorigenic effect of external irradiation, because of 
the high degree of replication of thyroid cells. This could amplify the 
possibility to fix and propagate mutational changes. More recently, 
controversial data (Elisei et al, 2001) suggested that RET/PTCs 
rearrangement in thyroid tumor is not restricted to the malignant 
phenotype, is not higher in radiation induced tumors compared with 
those naturally occurring, is not different after exposure to radioiodine 
or external radiation and is not dependent on young age.
The Chernobyl accident has increased the risk of childhood 
thyroid cancer. These tumors are more aggressive than sporadic
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tumors and have an unusually short latency period between the 
exposure and the disease. Moreover several studies indicate a lower 
female to male ratio than sporadic thyroid tumors in children (Moysich 
et al, 2002).
Since many authors described RET rearrangements in occult 
PTCs (Viglietto et al, 1995) and papillary micro carcinomas (Nasir et al, 
2000; Corvi et al, 2001), oncogene activation is considered an early 
event in thyroid carcinogenesis. This hypothesis is also supported by 
the evidence that transgenic mouse models of RET/PTCl and 
RET/PTC3, driven by a thyroglobulin promoter, develop multifocal 
thyroid tumors at an early age, and the tumors are histologically very 
similar to human papillary thyroid carcinomas, with ground glass 
nuclei, grooves and inclusions (Santoro et al, 1996; Russell et al, 
2000). However, RET/PTCl transgenic mice infrequently developed 
solid-type carcinomas, differently from what observed in RET/PTC3 
transgenic mice (Russell et al, 2000; Sagartz et al, 1997; Powell et al,
1998). In addition, the infection of short-term cultures of normal 
human thyroid cells with a retroviral vector expressing RET/PTCl alters 
nuclear morphology with similar or identical changes diagnostic of 
papillary thyroid carcinoma (Fischer et al, 1998) Interestingly, the 
failure to identify RET/PTC in poorly differentiated and anaplastic 
thyroid carcinomas (Soares et al, 1998) the apparent inability of
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papillary tumors harboring RET/PTC rearrangements to progress to 
less differentiated form (Tallini et al, 1998) and, on the contrary, the 
discovery of RET oncogene in transformed cells with apparent limited 
growth potential (Bond et al, 1994), point to a limited role for RET/PTC 
in the development of aggressive forms of thyroid cancer. Tallini et al. 
in 1998, analyzing 316 thyroid tumors concluded that only PTCs with 
alterations other than RET, e.g.: Trk gene, can progress to less 
differentiated, more malignant thyroid cancer. Recently, the same 
authors using immunohlstochemical techniques, identify RET 
rearrangements also in a low % (12.9%) of poorly differentiated 
thyroid carcinomas (PDC) (Santoro et al, 2002) but the proportion 
raises to 20% among poorly differentiated thyroid carcinomas with 
evidence of evolution from a papillary thyroid cancer. This finding may 
suggest that PDC could derive from dedifferentiation of TPC but do not 
support a role for RET/PTC In the development of the more malignant 
phenotype.
1.2.1.3 Restriction of RET oncogenic rearrangements to PTCs
Thyroid carcinoma is the only adult epithelial malignancy where 
specific chromosomal rearrangements have been identified. Thyroid 
cancer is a rare malignant disease of the endocrine system and has 
been clearly linked to external ionizing radiation exposure. I t  has been
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demonstrated that Chernobyl-related ionizing radiation exposure was 
directly related to the increased of developing papillary thyroid 
carcinoma risk in children from affected areas. Gene rearrangements 
involving the RET proto-oncogene, and less frequently NTRKl, have 
been shown to be causative events specific for papillary thyroid cancer 
(Bongarzone et al, 1996; Elisei, et al, 2001; Wajjwaiku et al, 1992; 
Beimfohr et al, 1999). However, in experimental models, transforming 
ability of the RET/PTCs oncogenes is not restricted to the thyroid 
epithelium. In fact in the case of transgenic mice carrying RET/PTCl 
gene under the control of the H4 promoter, Portella et al. report the 
developed of mammary adenocarcinomas, hyperplasia of sebaceous 
glands and pilomatrixomas (Portella et al, 1996). The specificity of 
these oncogenic rearrangements as peculiar feature for thyrocytes has 
been related to the higher frequency of proximity of the RET and H4 
loci in interphase nuclei of human thyroid cells, compared to nuclei of 
peripheral blood lymphocytes and mammary epithelial cells. Spatial 
contiguity of RET and H4 suggests a structural basis for generation of 
RET/PTCl rearrangement, because a single event could produce a 
double-strand break in each gene at the same site in the nucleus 
(Nikiforova et al, 2000a; Nikiforova et al, 2000b). This tendency is also 
proposed from the same author for RET/PTC3 rearrangement 
(Nikiforov et al, 1999). Moreover RET/PTC activation can be induced
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by irradiation of human thyroid tissues implanted in mice (Mizuno et 
al, 2000) but not in irradiated mice thyroid, probably because the 
chromosomal architecture of mice chromosome carrying RET locus 
during interphase is different from that of human thyroid cells. This 
finding could explain the high level of RET rearrangements in patients 
irradiated for benign diseases or in children exposed to radiation after 
Chernobyl accident, where the incidence of RET/PTC activation ranges 
from 60-70% versus the 5-30% of the spontaneous papillary 
carcinomas. On the other hand Yang et al (Yang et al, 1997) observed 
that thyroid ceils with DNA damage induced by exposure to ionizing 
radiation were resistant to apoptosis. In this context, the induced 
expression of wild type p53 might play an important role in promoting 
DNA end-jointing enzymatic activity in thyroid cells.
Follicular adenomas and carcinomas arise through an oncogenic 
pathway distinct from that of papillary carcinomas, characterized by a 
higher prevalence of activating mutations of all the three RAS genes 
and a greater predisposition to develop DNA copy abnormalities. In 
follicular carcinomas a fusion oncogene involving PAX8 and the 
peroxisome p ro I i fe ra to r-a cti va ted receptor PPARy has recently been 
described. PAX8 encodes a paired domain transcription factor essential 
for thyroid development. Such rearrangement was not found either in 
foilicular adenomas or in PTCs. The oncogene resulted from a
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chromosomal translocation t(2 ;3 ) (q l3 ;p25) In follicular tumors and 
displayed dominant negative suppression of wild type PPARy activities 
(Kroll et al, 2000).
In conclusion, a single thyrocyte can give rise to two different 
types of well-differentiated carcinomas, the papillary and the follicular. 
In this context the specific genetic alteration becomes crucial to drive 
the transformation of the thyrocytes towards the papillary (RET and 
NTRKl rearrangements) or the follicular phenotype (PPARy 
rearrangements or RAS point mutations). I t  is possible that papillary 
carcinomas lacking RET or TRK activation may carry rearrangements 
of other tyrosine kinase receptors rather than defects in genes 
involved in RET and TRK signaling pathways.
Finally it is worth mentioning that a few cases of familial 
papillary thyroid carcinomas (FPTCs) have been recently described 
although its mode of inheritance as well as its genetic and molecular 
bases are still poorly understood. No linkage to RET had been found in 
these tumors until Corvi (Corvi et al, 2001) demonstrated tha t one 
FPTC and the adenoma from the same patient carry a RET 
rearrangement (type PTCl) and that this rearrangement is absent in 
the germline. Furthermore, they excluded a RET haplotype sharing in 
two brothers of the same family. These results show tha t RET 
rearrangements can indeed be found in FPTC and confirm that RET is
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not involved in the inherited predisposition to FPTC. On the other 
hand, McKay (McKay et al, 2001) recently indicated the existence of a 
susceptibility locus for familial NMTC (a complex genetic disorder 
characterized by multifocal neoplasia and in particular by papillary 
thyroid carcinoma with a higher degree of aggressiveness than its 
sporadic counterpart) on chromosome 2q21.
1.2.2 RET activation in inherited and sporadic medullarv thvroid 
carcinomas
The C cells of the thyroid are derived from the neural crest and 
are believed to be the precursors from which medullary thyroid 
carcinoma (MTC) arises. As many as 75% of all MTCs are sporadic; the 
remaining hereditary forms of MTC are associated with Multiple 
Endocrine Neoplasia type 2 (MEN2) which was the firs t of the inherited 
endocrine neoplasia syndromes to be elucidated at the genetic level 
with the discovery in 1993 that germline mutations in the RET proto­
oncogene were present in affected individuals (Mulligan et al, 1993). 
Unlike other cancer syndromes, which are associated with inactivation 
of tumor suppressor genes, MEN2 arises as a result of activating 
mutations of the RET proto-oncogene.
Germline point mutations of RET are responsible for the inheritance of 
MEN2 cancer syndromes which are usually divided into three different
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clinical subtypes: MEN2A, MEN2B and FMTC, all autosomal dominant 
cancer syndromes.
The MEN2A subtype is characterised by MTC, pheochromocytoma, and 
parathyroid hyperplasia (Eng et al, 1996; Mulligan et al, 1995) 
whereas MTC, pheochromocytoma, ganglioneuromas of the intestinal 
tract and skeletal and ocular abnormalities characterise MEN2B. 
MEN2B is the most aggressive of the three sub-types, often displaying 
an earlier age of onset.
MTC is the only feature of FMTC and it usually develops at a later 
stage of life. The course of MTC in FMTC families is more benign and 
prognosis is good (Famdon et al, 1986).
1.2.2.1 Medullarv thyroid carcinoma
MTCs arise from thyroid C cells which are named for the ir ability 
to secrete calcitonin. Calcitonin is produced by MTCs and is useful as a 
specific MTC tumor marker. MTCs are well demarcated, firm , gray- 
white tumors that may have a gritty consistency due to calcifications. 
Almost all hereditary MTCs are bilateral or multifocal, and only 6% are 
solitary.
MTC spreads within the central compartment to pre tracheal lymph 
nodes (Level VI nodes), and frequently to upper mediastinal nodes 
(Level VII nodes). Further lymphatic spread can also occur to the
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lateral neck compartment, Including the jugular (Levels II, II, and IV 
nodes), posterior triangle (Level V nodes), and supraclavicular nodes. 
Primary MTC and lymph node métastasés can invade or compress 
adjacent structures, most commonly the trachea, recurrent laryngeal 
nerve, jugular veins and carotid arteries. Distant métastasés typically 
occur in the liver, lungs and bone and can be associated with small 
primaries. Patients who are diagnosed with MTC before it is palpable, 
rarely have lymph node métastasés. In contrast, most patients with 
sporadic MTC, or with hereditary MTC not detected by genetic 
screening, display a neck mass and have a very high rate of lymph 
node involvement (reviewed in Phay et al, 2000).
1.2.2.2 Multiple endocrine neoplasia type 2A fMEN2A^
In virtually all MEN2A, mutations affect the RET cysteine-rich 
extra cellular domain, each converting a cysteine to another amino 
acid, at codons 630, 634 (exon 11) or codons 609, 611, 618, 620, 
(exon 10). These mutations account for 98% of all the mutations 
associated with MEN2A; the most common mutation accounting for 
over 80% of all mutations associated with MEN2A affects codon 634 
and converts a cysteine into an arginine. Rarer mutations associated 
with MEN2A have been described such as an in-frame germline 
duplication of 12 and 9 bp in exon 11 (Hoppner and Ritter, 1997;
41
Review o f the literature
Hoppner et al, 1998) and de novo cases of MEN2A have been 
associated with two new germline mutations (at codons 634 and 640) 
on the same RET allele (Tessitore et al, 1999) or at codon 624 (Aguild,
1999). RETMEN2A oncoproteins display constitutive kinase activity due 
to ligand-independent dimerization. The substitution of one cysteine 
residue, leads to constitutive receptor dimerization and hence 
activation as the loss of an intramolecular disulphide bond results in an 
unpaired cysteine residue available to take part in an intermolecular 
disulphide bond between two mutant RET receptors (Asai et al, 1995; 
Santoro et al, 1995; Borrello et al, 1995). Consistent with this, 
transgenic mice in which the C634R mutation in the ret gene coding 
for the short isoform was expressed under the control of the human 
calcitonin promoter or under the MoMuLv LTR, develop C-cell tumors 
resembling human MTC (Michiels et al, 1997; Kawai et al, 2000). 
Interestingly, transgenic mice expressing the same mutation in the 
RET long isoform, developed both MTCs and papillary thyroid 
carcinoma (Reynolds et al, 2001).
1.2.2.3 Multiple endocrine neoplasia type 2B (MEN2B^
Most MEN2B cases (95%) are caused by the M918T mutation 
(exon 16) that is frequentiy a de novo mutation located on the allele 
inherited from the patient's father (Carison et al, 1994a). Other rarer
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(5%) intracellular mutations involve codon 883 (exon 15) in the RET 
tyrosine kinase domain. The M918T substitution is also found in 
sporadic MTC, with M918T mutation-positive tumours often displaying 
a more aggressive phenotype. Recently, infrequent germline missense 
mutations have been reported in MEN2B de novo cases: in exon 16 at 
codons 912 and 922 (Carison et ai, 1994b). Moreover, a double 
mutation at codons 804 and 806 has been found in a Japanese patient 
that had clinical features characteristic of MEN2B (Miyauchi et al,
1999). The reason why more than 95% of MEN2B cases are accounted 
by germline M918T and only fewer than 5% by A883F is unknown. The 
M918T mutation does not cause constitutive dimerization although 
GDNF stimulation seems to be necessary for the full activation of the 
MEN2B mutant RET (Bongarzone et al, 1998), and the overall 
activation leveis of the RET kinase it induces can hardly account for its 
high oncogenic potential (Borrello et al 1995; Santoro et al, 1995). 
Thus, RETMEN2B is probably more than simply an active RET kinase, 
and qualitative changes in RET kinase activity may be responsible for 
its specific neoplastic phenotype. RET methionine at codon 918 is 
highly conserved in receptor tyrosine kinases, and it maps in a loop of 
the kinase domain that is predicted to interact with the protein 
substrate. A threonine is found at the equivalent position in cytosolic 
tyrosine kinases, and the two kinase classes (receptorial and cytosolic)
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have different signaling specificities (Marengere et al, 1994). 
Accordingly, the MEN2B mutation converts the substrate-binding 
pocket of RET to resemble that of non-receptor tyrosine kinases such 
as c-src and c-abi (Carlson et al, 1994b; Hofstra et al, 1994). The 
change in substrate specificity can affect RET-mediated 
phosphorylation of intracellular proteins as well as the pattern of RET 
autophosphorylation sites. Both possibilities have been experimentally 
proven. The pattern of phosphorylated intracellular proteins differs in 
RETMEN2B- and RETMEN2A-expressing cells (Santoro et al, 1995). 
Moreover, phosphopeptlde mapping has shown that RETMEN2B 
autophosphorylation sites differ from those of wild-type RET and of 
RETMEN2A (Santoro et al, 1995; Liu et al, 1996; Murakami et al,
2002). Thus, the shift of RET autophosphorylation sites and of RET 
intracellular substrates, rather than the simple raise of RET kinase 
activity, may be crucial for the oncogenic activity of RETMEN2B alleles. 
I t  is not known how the A883F affects RET function. However, residue 
883 is located in a subdomain of RET that defines substrate preference 
(Smith et ai, 1997) thus suggesting that the alteration of substrate 
specificity may be the common etiologic thread that underlies the 
pathogenesis of MEN2B. The production of a mouse model of MEN2B 
by introduction of the corresponding mutation into the ret gene 
demonstrated that heterozygous mutant mice displayed several
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features of the human disease, including C-cell hyperplasia 
progressing to pheocromocytoma, while homozygous displayed more 
severe thyroid adrenal disease as well as male infertility. Only 
homozygous mice developed ganglioneuromas of the adrenal medulla 
and enlargement of the associated sympathetic ganglia (Smith-Hicks 
et al, 2000).
1.2.2.4 Tissues affected in MEN2 
Thyroid C cells
The biological role of thyroid C ceils is the production of calcitonin, a 
peptide hormone, and its secretion in response to raised blood calcium 
levels. Calcitonin then acts to lower blood calcium levels by increasing 
uptake into bone. C cells also produce a number of other peptide 
hormones, but the biological significance of these is not clear (Scopsi, 
1991). The neural crest origin of at least some thyroid C cells was 
shown by grafting the quail neural tube into chickens (Le Douarin, 
1970). In mammals, the vagal neural crest progenitors of C cells 
migrate into the ectoderm of the fourth pharyngeal pouch, forming the 
ultimobranchial body. At around 12.5 days post coitum (dpc) in the 
mouse, the ultimobranchial bodies fuse with the thyroid diverticulum, 
which is formed from an outgrowth of the endoderm from the back of 
the tongue which bifurcates around the trachea (Thiler et al, 1989). At
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birth, the ultimobranchial component is indistinguishable as a separate 
entity from the thyroid diverticulum component, with C cells dispersed 
in parafollicular positions between thyroid follicles.
Although it is generally accepted that C cells are neural crest-derived, 
some authors argue that at least some C cells may have an 
alternative, endodermal origin. The strongest evidence to support this 
claim is the existence of mixed medullary-follicular tumours which are 
immunopositive for both follicular cell markers, such as thyroglobulin, 
and neuroendocrine markers such as calcitonin gene related peptide 
(CGRP), chromogranin A and carcinoembryonic antigen (Holm et al, 
1987; Ljungberg et al, 1983; Hales et al, 1982; Marth et al, 1996). 
Moreover, the precise lineage relationships between C cells and other 
neural crest derivatives is unknown and similar biochemical properties 
to enteric neurons and their origin from vagai neural crest, suggest 
that they are more closely related to gut neuroblasts than to adrenal 
chromaffin cells, which arise from multi potent cells of the trunk neural 
crest.
Studies on RET expression have also suggested that the C cell 
population may be heterogeneous. In the postnatal rat, a small 
number of C cells were said to be immunopositive for RET, although it 
was not reported whether deveioping C cells in the embryo were aiso 
positive (Tsuzuki et al, 1995). Similarly, in situ hybridisation of RET
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gave a signal in only a subpopulation of human C ceils (Fabien et al, 
1994). Nevertheless, it is possible that all C cells express RET, but that 
in the majority of them it is below the threshold of detection.
The role of RET In normal thyroid C cells is not clear. In fact, RET null 
mice appear to have a normal thyroid C cell population (Pachnis, 
unpublished data). This suggests that RET is not directly involved in 
thyroid C cell development, despite the fact that it is expressed in the 
neuroectodermai lineage in the pharyngeal arch region at 8.5-9.5 days 
post coitum (Pachnis et al, 1993). The development of other vagal 
crest derivatives (mid and hindgut enteric neurons and the superior 
cervical ganglion) is RET-dependent (Durbec et al, 1996).
The adrenal chromaffin ceiis
Chromaffin cells of the adrenal medulla are derived from the trunk 
neural crest which also gives rise to the sympathetic ganglia 
(Anderson et ai, 1993) and foregut enteric neurons (Dubrec et al, 
1996). As with C ceils, there is no apparent defect in the adrenal 
medulla in RET knockout mice, suggesting that RET is not directly 
involved in their formation. The development of foregut enteric 
neurons is also RET-independent (Durbec et al, 1996). Although RET 
expression is detected by in situ hybridization in the sympathetic 
ganglia at 14.5 days post coitum in the mouse embryo, no expression
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can be detected in embryonic adrenal chromaffin cells (Pachnis et al, 
1993). Only isolated chromaffin cells show RET immunopositivity in the 
adult rat (Tsuzuki et al, 1995). Human phaeochromocytomas show 
relatively strong expression of RET mRNA even though the signal 
obtained from chromaffin ceiis is weak (Santoro et al, 1990).
The parathyroid gland
Parathyroid glands are endocrine structures which release parathyroid 
hormone in response to depleted levels of blood calcium. These 
structures are derived from the endoderm of the third branchial pouch 
(Manley and Capecchi, 1995): In the developing embryo, RET is 
expressed in this region of endoderm but its role is unknown.
1.2.2.5 Familiai medullarv thyroid carcinoma fFMTO
FMTC mutations can be found either in the extraceilular or in the 
tyrosine kinase domain. The ones occurring in the extraceilular domain 
of RET are usually a set of substitutions of cysteines 609, 611, 618, 
620 (exon 10) and both 630 and 634 which are also found associated 
with MEN2A, whereas in the tyrosine kinase domain, mutations occur 
at residues 768, 790, 791 (exon 13), 804, 844 (exon 14) or 891 (exon 
15). Rare mutations have been recently reported, such as a 9-base 
pair duplication in exon 8 in an FMTC family (Pigny et al, 1999) or
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mutations at codons 804 and 778 on the same RET allele which are 
associated with both FMTC and prominent corneal nerves (Kasprzak et 
al, 2001). FMTC mutations occurring in the intracellular RET domain 
were thought to be infrequent and only a small number of families 
bearing a RET mutation within exons 13, 14 and 15 had been 
described. In the past two years the frequency of detection of these 
mutations has increased (Niccoli-Sire et al, 2001) due to more 
accurate analysis and screening. Of note, mutations in exon 13 at 
codons 790 and 791 and in exon 14 at codon 804, until recently 
associated with the FMTC phenotype, have also been found in MEN2A. 
Cysteine mutations in the RET extracellular domain sometimes induce 
the FMTC phenotype and in contrast with what happens in MEN2A 
families, the substitution at codon 634 occurs only in 30% of the cases 
whereas mutations at codons 609, 611, 618, 620, 630, occurred in 
60% of the FMTC families (Ponder and Smith, 1996). The transforming 
activity of RET with a substitution in cysteine 609, 611, 618, 620 or 
630 was significantly lower compared to that of RET with the cysteine 
substitution at codon 634. This low transforming activity could then 
favour the development of FMTC rather than MEN2A.
No data are yet available on the mechanisms of activation of 
FMTC mutations occurring in the RET tyrosine kinase domain. Patients 
with RET mutations in exons 13, 14 and 15 exhibit a mild C cell
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disease phenotype (Berndt et al, 1998; Fattoruso et al, 1998) 
confirmed by in vitro studies. In fact, mutants expressing E768, V804 
and S891 RET mutations display lower transforming activity (Pasini et 
al, 1997; Iwashita et al, 1999) compared to RET substitutions at 
codons 634, 918 or 883, strongly associated with MEN2A and MEN2B 
respectively. Computer modelling has suggested that the E768D 
substitution modifies the kinase activity of the receptor by altering 
substrate specificity or ATP-binding capacity (Pasini et al, 1997). As for 
its location, also the substitution at position 804 may exert an 
activating effect by altering the kinetics of interactions with normal 
cellular substrates or by modifying the range of substrates that are 
phosphorylated (Bolino et al, 1995; Eng et al, 1995; Iwashita, et al, 
1999; Pasini et al, 1997).
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Figure 6. RET oncogenic mutations. Activating germline mutations 
of RET are responsibie for the MEN2A syndrome which comprises three 
different diseases: MEN2A, MEN2B and FMTC.
1.2.2.6 Sporadic MTC
MTC is sporadic in 75% of all cases and hereditary in the rest. 
Hereditary MTC is weii defined: germline gain-of-function mutations in
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the RET proto-oncogene cause multiple endocrine neoplasia type 2 
(MEN 2) ( Eng et ai, 1996a). However, the majority of cases are 
sporadic. The aetiology of sporadic MTC, similar to most 
neuroendocrine tumours, remains elusive. Although LOH at various loci 
( Mulligan et al, 1993), and somatic mutations in RET, mainiy at codon 
918, occcur in MTC ( Hofstra et al, 1994; Eng et al, 1995; Eng et al, 
1996a, 1996b, 1999), the aetiology and pathogenesis of these 
sporadic tumours remains largely unknown. Somatic RET mutations 
are found in up to 70% (mean 30-50% ) of DNA from sporadic 
tumours (Eng and Mulligan, 1997). These somatic mutations are often 
heterogeneously present in tumour DNA, indicating that they more 
likely occur during clonal evolution rather than presenting the initial 
step of carcinogenesis. Deletions of several chromosome arms ( Ip ,  3p, 
3q, l i p ,  13q, and 22q) have been reported in up to 38% (Mulligan et 
al, 1993). No tumor suppressor gene has been identified yet. Recently, 
over-representation of a germline polymorphic sequence variant 
located within exon 14 of the RET proto-oncogene at codon 836 (nt C, 
2439C to T, S836S) was found to be associated with sporadic MTC, 
with a relative risk of approximately 3 (Gimm et al, 1999).
Mutations at cysteine codons 609, 611, 618, 620, 630, 634 
appear also in sporadic MTC cases and recently three new somatic 
missense mutations (at codons 639, 641 and 922) of the RET proto­
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oncogene associated with sporadic MTC have been described (Kalimin 
et ai, 2001).
Recent studies (Feldman et al, 2000;Brauckhoff et al, 2002) 
have reported cases of patients harboring RET germline mutations in 
exons 14 and 15 (at codons 790, 791, 804) resulting in papillary micro 
carcinoma. Moreover, Rey et al. (Rey et al, 2001) also described the 
case of a kindred in which a novel single point germline RET mutation 
(K603E in exon 10) co segregates with medullary and papillary thyroid 
carcinomas. Despite the low number, these observations suggest that 
there might be a correlation between the occurrence of PTC and RET 
germiine mutations in exons 13 and 14 that may play a role in the 
pathogenesis of PTC. Of note, PTC seems to be present only in 
patients with low penetrance RET germline mutations. I t  remains an 
open question whether the simultaneous occurrence of inherited MTC 
and PTC is coincidental or the result of partly common pathogenic 
pathways. Reynolds et al. (Reynolds et al, 2001) found the co­
existence of MTC and PTC in transgenic mice expressing the long 
isoform of MEN2A RET and suggested that this might be due to the 
possible existence of an ultimobranchial stem cell of endodermal 
origin, which gives rise to a subset of both thyroid follicular cells and 
C-cells (Kovacs et al, 1994).
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In conclusion, the genotype/phenotype associations in MEN2 
reflect differences in behavior and function among the RET mutant 
forms. The above data suggest a model in which there are tissue 
specific differences in sensitivity to RET activation. All RET activating 
mutations in fact, are sufficient to induce tumorigenesis in the thyroid 
glands and MTC is associated with all MEN2 subtypes. On the other 
hand, phaeochromocytoma and hyperparathyroidism are mainly found 
in association with the most penetrant of RET mutations affecting 
cysteine 634, suggesting that high transforming activity is required to 
induce abnormal growth in these tissues.
1.2.2.7 Diagnosis and management of MEN2
The prognosis for MEN2 patients is very good with early 
diagnosis and intervention, thus implying that adequate testing is 
required to screen subjects at risk for MTC. Currentiy, early genetic 
screening for RET mutations is considered the standard care for MEN2, 
since patients having a MEN2/FMTC-specific germline mutation have a 
high risk of developing MTC. Prophylactic thyroidectomy is 
recommended before the age of 6 years (reviewed in Gimm et al, 
2001) as every single C-cell inherits the genetically determined 
potential to become neoplastic. Clinical research concentrates on 
finding an existing genotype-phenotype correlation, mutations which
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are associated with a late age of onset, that would allow postponing 
surgery, thus preserving the thyroid untii adulthood or restricting the 
extent of surgery. Several mutations such as E768D and V804M seem 
to qualify for such a recommendation (Gimm et al, 2001). MEN2B- 
associated MTC is the most aggressive and early diagnosis is required 
and total thyroidectomy is recommended as early as 1 year. Given 
that even low penetrance RET mutations, particulariy codon 804 
mutations, might exist in MEN2, it might be wise for all individuals who 
present MTC to undergo RET testing. The discovery of an occult 
germline RET mutation in an apparently sporadic MTC case means that 
the individual has MEN2. In order to simplify the detection of RET 
missense mutations, in a very recent paper (Kim et al, 2002), a 
method for the rapid mutation anaiysis of gene sequences has been 
proposed using oligonucleotide microarrays instead of the commonly 
used analysis of RET mutations by single-strand conformational 
polymorphism or direct sequencing. This might represent an effective 
diagnostic genetic tool to test for the presence of MEN2 mutations at 
early stages.
As MTC respond very poorly to chemotherapeutic agents and 
total thyroidectomy is the oniy way to treat these tumors, the 
availability of inhibitors specific for RET oncoproteins could help in 
developing new therapeutic strategies for RET-associated diseases.
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Carlomagno et al. (Carlomagno et al, 2002) have very recently 
demonstrated that the pyrazolo-pyrimldlne PPl blocks tumorigenesis 
induced by RET/PTC cytoplasmic oncogenes by inhibiting RET 
enzymatic activity and thus its transforming effects. Our results as 
well, suggest that PPl treatment would represent a promising new 
strategy to selectively target RET oncogenic products for destruction 
holding promise for MTC therapy.
1.2.3 RET germline inactivating mutations in Hirschoruna disease
Hirschsprung disease (HSCR), or colonic aganglionosis, is a 
common congenital disorder (one in 5000 live births) leading to 
intestinal obstruction or chronic constipation (Parisi and Kapur, 2000). 
Most HSCR cases are sporadic, however 15-20% are familial forms 
and genetic analysis has identified mutations in pathways related to 
RET, endothelin and in two transcription factors. Sox 1 and the SMAD- 
interacting protein-1 (S IP l) (Parisi and Kapur, 2000; Wakamatsu et al, 
2001; Cacheux et al, 2001). Heterozygous mutations of GDNF and 
NTRN have also been identified in a small fraction of HSCR patients 
(Parisi and Kapur, 2000) but no mutations have been described for 
RET coreceptors (Angrist et al, 1998; Myers et al, 1999; Onochie et al, 
2000; Vanhorne et al, 2001) even though G fraal knockout mice are 
phenotipically very similar to RET and GDNF -/-  mice (Cacalano et al,
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1998; Enomoto et al, 1998). However, RET seems to be the major 
gene involved in HSCR; even when the major mutation is in the 
endothelin receptor B (EDNRB) gene (Puffenberger et al, 1994), RET 
variants make some contribution to susceptibility and homozygous 
Ret-null mice have full sex-independent penetrance of aganglionosis 
(Schuchardt et al, 1994). Moreover, even the mutations affecting RET 
ligands are not sufficient by themseives to induce the HSCR 
phenotype, but contribute to the disease when associated with other 
mutations in RET (Parisi and Kapur, 2000).
Inactivating mutations of one allele of the RET proto-oncogene have 
been detected in haif of the dominantly inherited cases of HSCR that 
displays incomplete penetrance, and in one third of HSCR sporadic 
cases (Eng, 1996; Eng and Mulligan, 1997). RET mutations are spread 
throughout the coding sequence and include deletion, insertion, frame 
shift, nonsense and missense mutations (Eng and Muliigan, 1997; 
Parisi and Kapur, 2000). Most of these mutations impair RET function 
(Parisi and Kapur, 2000; Iwashita et al, 2001), thus suggesting that 
HSCR results from RET haploinsufficiency, but the allelic heterogeneity 
at the RET locus in HSCR is associated with various mechanisms of 
action leading to RET dysfunction (Pelet et al, 1998; Iwashita et al, 
2001). Mutations iocated within the extracytopiasmic domain impair 
RET maturation and its translocation to the plasma membrane
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(Carlomagno et al, 1996; Iwashita et al, 1996). This probably results 
in a decrease in the amount of the RET protein at the celi surface, 
which is insufficient to trigger RET signalling in enteric neuroblasts 
during embryogenesis. HSCR mutations in the RET tyrosine kinase 
domain affect the catalytic activity to different extent. Some of them 
completely abolish the receptor kinase activity, others interfere with 
the binding of components of RET signalling such as PLC-y for the 
E762Q substitution (Iwashita et al, 2001) She, IRS-2 or FRS2 
(Geneste et al, 1999; Melillo et al, 2001b; Melillo et al, 2001a; 
Bordeaux et al, 2000). Recently, Bordeaux et al. (Bordeaux et al, 
2000) suggested that RET can induce caspase dependent apoptosis in 
the absence of its ligand. HSCR may then result from apoptosis of 
RET-expressing enteric neuroblasts since HSCR mutations render this 
proapoptotic activity ligand insensitive.
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Figure 7. RET inactivating mutations. Inactivating mutations of 
RET cause the impaired development of the enteric nervous system 
which is responsible for the Congenital megacolon or Hirschprung's 
disease (HSCR)
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1.2.4 Co segregation of MEN2A/FMTC and HSCR
In rare families, MEN2A/FMTC and HSCR co-segregate (Mulligan 
et al, 1994; Decker et al, 1998; Takahashi et al, 1999) and affected 
individuals carry a single substitution at one of the four cysteines in 
the extra cellular RET domain (codons 609, 611, 618 and 620). The 
reason why a single mutation can display antagonistic effects is still 
under current studies. I t  is possible to speculate that this is due to the 
differences in the timing of RET expression in each particular tissue 
that might differently affect tissue development in neurai-crest derived 
cells. These mutations result, in uncontrolled cellular proliferation in 
endocrine tissues and on the other hand, result in a lack of neural 
growth in the enteric system (Takahashi et al, 1999). Genetic or 
environmentai factors might also influence the clinical expression of 
the enteric phenotype. In endocrine tissues in fact, these cysteine 
substitutions have a dominant effect, whereas it is not yet clear if the 
loss or inactivation of the wild type RET allele, in the enteric system, is 
associated with the HSCR phenotype.
Experimental data demonstrated that RET MEN2A/HSCR 
mutations markedly decrease RET cell surface expression (Ito  et al, 
1997) resembling the typical HSCR mutations of the RET extra cellular 
domain. Interestingly, both transfection experiments and biochemical 
analysis have shown that the cysteine codon substitutions were also
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able to cause ligand independent dimérisation, activation and 
transformation as do the classical MEN2A cysteine substitutions (Asai 
et al, 1995; Santoro et al, 1995; Borrello et al, 1995), although to 
different extents. Since these mutations trigger the development of 
medullary thyroid carcinoma, as weil as pheochromocytoma, the 
mislocalization of the receptors affect pathways not involved in cell 
proliferation but probably controlling other pathways such as cell 
movement and migration, probably essential for neuronal 
development.
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Disease Genetic aiteration Pathogenic mechanism
RET
PTCs chromosomal rearrangements constitutive TK activity
MEN2A germline point mutations in the 
cysteine-rich domain
constitutive disulphide linked 
dimerization
MEN2B germline point mutations in RETTK 
domain
constitutive TK activity altered 
substrate specificity
FMTC germline point mutations
- in the cysteine-rich domain
- in RETTK domain
constitutive dimerization 
constitutive TK activity? altered 
substrate specificity ?
HSCR germline point, frame shift, missense 
mutations in:
- RET extracellular domain
- RET tyrosine kinase domain
- RET COOH terminus
impairment of RET cell surface 
expression
partial or total loss of RET TK activity 
impairment of binding of docking 
proteins
Table 2. Involvement of RET in human pathologies
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1.3 Aim of the present study
The aim of the work in the following chapters was to study of the 
expression of different RET mutants in order to highlight their 
biological role in diverse cellular contexts. In particular, we focused on 
gain of function cysteine mutations that are responsible for medullary 
thyroid carcinoma (MTC) by causing the covalent dimerization of RET, 
leading to ligand-independent activation of its tyrosine kinase. In this 
context, the association of Cys®°  ^ ,Cys®^° and activating mutations with 
HSCR is stiil an unresolved paradox. To address this issue, we have 
developed a transgenic model for human diseases (specifically. 
Multiple Endocrine Neopiasia type 2 and Hirschsprung disease) through 
the insertion of a gain and loss of function RET mutation, the RET^ z^oR 
into the mouse genome.
Since a mouse model of MTC which reflects the human tumour could 
be used for studies aimed at deveioping therapeutic strategies for 
carcinomas sustaining RET activation, we have also studied the in vitro 
effects of a tyrosine kinase inhibitor PPl, that we propose as possibly 
representing a potential treatment strategy and thus meriting testing 
using in vivo models such as the one we have generated.
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2. MATERIALS AND METHODS
2.1 Cell Culture
Mouse fibroblast NIH3T3-untransfected cells were grown in 
DMEM containing 10% calf serum whereas NIH3T3-transfected 
cells were grown In DMEM containing 5% fetal calf serum (PCS). 
HEK 293T cells were grown in DMEM supplemented with 10% 
PCS. The human TT celi line was cultured in Ham's F-12 (Life 
Technologies, Inc.) supplemented with 15% PCS. SK-N-MC 
neuroepitheiioma ceils were grown in DMEM containing 10% 
PCS. The MDA-MB-231 cell line was cultured in RPMI 
supplemented with 10% PCS.
2.2 Maintenance of cell cultures
Culture media were made fresh every 7 days. Adherent cells 
were split using 0.25% trypsin/EDTA (once detached, the cells 
were mixed with an equal volume of growth medium to 
inactivate the trypsin) and harvested by centrifugation at 1000 
rpm for 10 minutes. The cell pellet was resuspended in growth 
medium and an aliquot was diluted in trypan blue for counting . 
only viable cells (those that excluded trypan blue) were counted.
2.3 Storage of cell lines in liquid nitrogen
Stocks of ceils were kept under liquid nitrogen at a density of 
1X10^ cells/ml in growth medium containing 30% serum and
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10% (v/v) dimethyl sulphoxide (DMSO-Sigma cell culture). 1 ml 
aliquots of the cell suspension were aliquoted into Nunc™ 
cryovials and the vials were frozen overnight at -80°C before 
transferring to liquid nitrogen for long term storage.
Cells were removed from liquid nitrogen when required and 
thawed rapidly. The cell suspension was diluted to 10 ml in 
proliferation medium and washed 3 times by centrifugation to 
remove the DMSO before seeding in growth medium.
2.4 Preparation of expression constructs
2.4.1 Sub-cloning into expression vectors
Before transfection, each cDNA was subcloned Into the suitable 
expression vector, pcDNA.3 (Invitrogen). cDNAs were excised 
with the appropriate restriction enzymes and purified from 
agarose gei slices using the Qiagen™ Qiaquick gel extraction kit, 
according to manufacturer's instructions. Vectors were restricted, 
the termini dephosphorylated and purified for ligation. Ligations 
were carried out at 15°C overnight using T4 iigase (Boeringher 
Mannheim), according to manufacturer's instructions.
2.4.2 Restriction enzvme digestion of DNA
Reactions were carried out in 20pl volume following the protocols 
of Maniatis et al 1993. Loading buffer was added to the digest 
prior to electrophoresis. Restriction fragments were visualised by
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electrophoresis on agarose IX TBE buffered gels stained with 
2.5ng ethidium bromide.
2.4.3 Tansformation of competent bacteria with expression 
vectors
2.4.3.1 Preparation of competent bacteria
E.coii, strains HBlOl and JM109, stored in 300ml aliquots 
at -80°C were spread onto a Luria Bertani (LB) agar plate and 
grown overnight at 37°C. The same day, a single colony of 
bacteria was picked and used to inoculate 6mi of LB medium in a 
15ml tube (Falcon) and grown overnight at 37®C with shaking at 
approximately 250 rpm. 4ml of the overnight culture were 
transferred into a l i  conical flask with a loose cap containing 
400mi of LB medium. The culture was incubated for 2 hours at 
37°C with shaking at approximately 250 rpm. After 2 hours. Zero 
point five ml samples of the culture were taken at 15 minute 
intervals and the optical density (O.D.) at 590nm measured. 
When the O.D. was between 0.3 and 0.375, the culture was 
judged to be in a log phase of growth and transferred to 50ml 
Falcon tubes which were cooled on ice for 10 minutes. Bacteria 
were collected by centrifugation at 2500rpm for 12 minutes at 
4°C. the medium was discarded and each pellet was carefully re­
suspended in 10ml of Ice-cold, autoclaved lOOmM calcium 
chloride, pooled and kept in ice for at least 30 minutes to
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increase the efficiency of transformation. 0.45mi 80% giyceroi 
was added to the suspension to give an 8% finai giyceroi 
concentration. The compétents ceiis were divided into 300pi 
aiiquots and immediately frozen in dry ice before storing at -  
80°C.
2.4.3.2 Transformation of competent bacteria
E. coil bacteria were transformed by heat shock. 17.4pi of 
2-mercaptoethanol was added to Im i of sterile H20 the solution 
was mixed and cooled on ice. An aliquot of frozen competent 
ceils were thawed on ice, added to lOpi of the cold 2- 
mercaptoethanol solution in a sterile 15ml round bottomed tube 
and left on ice for 3 minutes. Approximately 20ng of DNA was 
added, the tubes were tightly capped, and left on ice for 40 
minutes. The bacterial suspension was heat shocked by placing it 
in a 42°C water bath for 2 minutes and then cooled on ice. 1ml 
of LB broth (pre-warmed to 37°C) was added and the bacteria 
were incubated in aerated tubes for 1 hour at 37°C with shaking 
at approximately 250rpm. Aiiquots of transformed cultures were 
plated onto LB agar plates containing lOOpg/mi ampiciiiin and 
grown overnight at 37°C. Individual colonies were selected and 
analysed by alkaline mini-preparations of plasmid DNA, which 
were mapped by restriction enzyme digestion to identify clones
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containing the required, single copy insert in the correct 
orientation.
2.4.4 Alkaline mini preparations of oiasmid DNA
Individual preparations of colonies were inoculated into 
4mi of LB broth containing lOOpg/mi ampiciiiin and incubated 
overnight at 37°C with shaking. 1.5ml of the overnight culture 
were transferred Into a 1.5ml microcentrifuge tube and bacteria 
were collected by centrifugation at 5000rpm for 5 minutes in a 
microcentrifuge. The remainder of each culture was stored at 
4®C. The supernatant was removed and the bacteria were 
resuspended in lOOpi giucose/tris/EDTA (25mMTris/HCi pH8.0, 
10 mM EDTA pH8.0, 50mM glucose). The bacteria were iysed by 
the addition of 200pi of o.2M NaOH containing 1% SDS. The 
contents of the tube were mixed and put on ice for 5 minutes. 
150pi of 5M potassium acetate was added to the lysate, which 
was incubated on ice for a further 10 minutes. After mixing, the 
precipitate was collected by centrifugation in a microcentrifuge at 
13000 rpm for 10 minutes at room temperature. The 
supernatant was transferred to a new microcentrifuge tube and 
the plasmid was precipitated for 1 hour at -20°C after addition 
of 10% (v/v) sodium acetate pH5.2 and two volumes of 100% 
ethanol, pre-cooied to -20°C. The precipitate collected by
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centrifugation was washed twice with ethanoi 70%, pre-cooied to 
-20°C. The ethanoi was discarded and without drying, the peiiet 
was re-suspended in lOOpi TE buffer (lOmM Tris.HCi pH 8.0 
ImM EDTA pH 8.0). RNA was precipitated adding lOOpi iithium 
chloride, vortexing and centrifugating at 13000rpm for 10 
minutes in a bench-top microcentrifuge to bring down the 
lithium-rRNA precipitate. The supernatant was transferred to a 
new microcentrifuge tube and DNA was precipitated and washed 
with ethanoi 70%. The finai peiiet was dried and resuspended in 
TE buffer.
2.4.5 Maxi preparations of oiasmid DNA
Colonies of bacteria which contained the expression vector 
containing a single copy of the required insert in the correct 
orientation were chosen for maxi-preparations of plasmid DNA 
using Qiagen Plasmid Maxi Kit with Qiagen tip 500, according to 
manufacturers instructions. DNA was resuspended in TE buffer 
pH 8.0. Purity was checked by spectrophotometry and integrity 
of the construct was assessed by restriction enzyme digestion.
2.5 Transfection and cloning of mammalian ceil lines
NIH3T3, SKNMC and 293T ceiis were used in transfection 
studies. Transient transfections were carried out using either the 
iipofectamine or calcium phosphate methods. Lipofectamine was
69
Materials and Methods
used according to the manufacturer' instructions (Gibco-BRL, 
Gaithersburg). When using the caicium phosphate method, ceiis 
were transfected as previously described (Bongarzone et ai, 
1993). Transformation foci were selected in DMEM with 5% caif 
serum. E25-427 ceiis, NIH3T3 ceiis overexpressing the human 
TRK proto-oncogene, were kindiy provided by Dr. Mariano 
Barbacid and grown in DMEM supplemented with 10% caif 
serum. HEK 293T cells were grown in DMEM supplemented with 
10% PCS and transiently transfected by calcium phosphate 
precipitation.
2.6 Cell stimulants and inhibitors
Ceiis were serum-starved for 12 or 24 hours prior to the 
addition of GDNF and EGF respectively. PPl inhibitor [4-amino-5- 
(4-methyiphenyi)-7-(-t-butyi)pyrazoio-D-3,4-pyrimidine] was 
obtained from BioMoi Research Laboratories, dissolved in DMSO, 
and diluted into culture medium at the time of experimentation 
to a finai concentration of 1 pM. PP2, PP3, Genistein, and 
Herbimycin from Caibiochem (Novacaibiochem Corporation) were 
dissolved in DMSO and, diluted into the culture medium to finai 
concentrations of PP2 (1 pM), PP3 (1 pM), Genistein (100 pM), or 
Herbamycin (0.1 pM).
Lactacystin was purchased from Sigma Chemical Co., dissolved 
In DMSO and diluted in culture medium to a finai concentration
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of 2 pM. MG132 was purchased from Caibiochem 
(Novacaibiochem Corporation), dissolved in DMSO, and then 
diluted In culture medium to a finai concentration of 10 pM. 
Chioroquine, from Sigma Chemical Co., was dissolved in water 
and diluted In culture medium to a final concentration of 100 pM. 
The human recombinant epidermal growth factor was from Life 
Technologies, Inc. (13247-051) and was diluted into the culture 
medium to a finai concentration of 20 ng/mi.
2.7 Ceil Motiiitv Assav
Migration of RET-expressing ceiis was determined using an in 
vitro model of wound repair as described previously (Sato and 
Rifkin, 1988.). The semiconfiuent monolayers were scraped with 
a 10pm sterile plastic micropipette tip, and cellular debris was 
removed by washing with serum-free DMEM. The monolayers 
were incubated in DMEM with or without 1 pM PPl for 12 h. Ceil 
migration was observed using a phase contrast microscope 
under x200 magnification. Each condition was examined in 
duplicate, and the experiments repeated at least three times.
2.8 Immunofiuorescencent staining
Ceiis were seeded on chambersiides and immunostaining 
carried out after 24 hours to allow recovery of the ceil surface 
protein portfolio after exposure to trypsin during harvesting. Ail
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incubations were carried out at room temperature and antibodies 
were centrifuged prior to the addition to ceiis in order to remove 
any precipitate. Ceiis were washed 3 times in PBS pre-warmed to 
37®C and fixed in 4% formaldehyde In PBS for 15 minutes. The 
fixative was removed by washing the chamber slides with PBS. 
Cells were incubated with BSA 5% in PBS for 30 minutes to 
reduce non specific binding of the secondary antibody. Cells were 
incubated in primary antibody diluted in PBS with or without 
0.1% Triton X-100. Immunostaining with primary antibodies was 
followed by incubation with either rhodamine-conjugated 
anti rabbit (Dako) or FITC-conjugated anti-IgG from Jackson 
Immunoresearch (West Grove, PA). Confocai images were 
obtained using a Bio-Rad MRC-1024 confocai microscope.
2.9 Immunoprécipitation and Western Blot Anaivsis 
Cells were washed with ice-cold PBS and Iysed on ice for 20 
minutes in modified radioimmune precipitation assay (RIPA) 
buffer (50 mM Hepes, pH7.5, 150 mM NaCI, 10% glycerol, 1% 
Triton X-100, 0.1% sodium dodecyl sulphate (SDS), 1% sodium 
deoxichoiate, 100 mM NaF, 0.5 mM NasV04 , ImM EGTA, 1% 
Nonidet P-40, 0.1 U/ml aprotinin, ImM
phenyimethyisuiphonyifiuoride (PMSF), 10 pg/mi ieupeptin and 4 
pg/m pepstatin A). Protein samples were immunoprecipitated 
with the specific antisera. Protein concentration was estimated
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by a modified Bradford assay (Bio-Rad, Munich, Germany). 
Antibodies were added to lysates containing equai amounts of 
protein, and samples were incubated on ice for 1 hour. To 
precipitate antibody-antigen complexes, 40pl of a 50% 
suspension of Protein-A or protein-G sepharose beads
(Amersham Pharmacia) were added to the lysate following 
rotation at 4°c for at least 2 hours. The immunoprecipitates were 
collected by centrifugating and washed three times in wash 
buffer (lysis buffer without detergents). Pellets were then boiled 
in SDS sample buffer and immune complexes were separated by 
electrophoresis on 8% SDS-PAGEs, transferred onto
nitrocellulose membranes (Miiiipore Co., Bedford, MA), and 
analyzed by immunoblotting with the appropriate antibodies. For 
whole ceil lysates, ceiis were iysed in SDS lysis buffer (62.5 mM 
Tris-HCI (pH 6.8) and 2% SDS). Total extracts were separated 
by SDS-PAGE.
Immunoreactive bands were visualized using horseradish
peroxidase-conjugated anti rabbit or antimouse antisera (Santa 
Cruz Biotechnology) and detected with the enhanced 
chemiiuminescence kit (enhanced chemiiuminescence detection 
reagents; Amersham Pharmacia Biotech, Little Chaifort, United 
Kingdom).
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Antibodies used in this study were anti-RET poiycionai antibody 
(C-19) raised against a peptide corresponding to an amino acid 
sequence mapping at the COOH terminus of RET was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). To stain RET at 
the cell surface in experiments of immunofiuoresence, we used a 
monoclonal non-purlfied serum directed against the extracellular 
domain, kindiy provided by Dr. Tagiiabue (Istituto Nazionale 
Tumori, Milano). The following antibodies were also used: mouse 
antiphosphotyrosine (4G10; Upstate Biotechnology, Inc., Lake 
Placid, NY); Vincuiin monoclonal antibody (V-4505; Sigma 
Chemical Co., St. Louis, MO); Tubulin poiycionai antibody (T- 
3526; Sigma Chemical Co.); TRK polyclonal antibody (Santa 
Cruz Biotechnology); EGFR poiycionai antibody (sc-03; Santa 
Cruz Biotechnology, CA); ubiquitin monoclonal antibody (MMS- 
258; Babco) for Western blots; and ubiquitin monoclonal 
antibody (FKl, which recognizes only poiyubiquitin-protein 
conjugates; Affiniti BioReagents, Inc.), Cbi poiycionai antibody 
(C-15 Santa Cruz Biotechnology); and clathrin monoclonal 
antibody (MAl-065, Affiniti BioReagents, Inc.), anti-Shc rabbit 
poiycionai antibody (UBI), anti-Crk monoclonal antibody 
(Transduction laboratories), anti-Ptyr (UBI), anti-Src (clone 
G D ll) mouse monoclonal antibody (UBI), anti-Shp2 rabbit 
poiycionai antibody (Santa Cruz Biotechnology), anti-p38 MAP 
kinase and anti-phosphop38 MAP kinase (Santa Cruz
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Biotechnology). FITC-iabeied phaiioidin (Sigma Chemical Co.) 
was used to detect filamentous actin (finai concentration 125 
ng/mi).
Secondary antibodies were from Santa Cruz Biotechnology.
2.10 RET Kinase Activity
RET kinase activity was assessed in vitro by its ability to 
autophosphoryiate and phosphoryiate myelin basic protein (MBP; 
Sigma). Protein extracts were immunoprecipitated with anti-RET 
or anti-TRK antibodies as described above and washed twice with 
lysis buffer and once with incubation buffer (50 mM HEPES (pH 
7.2), 20 mM MnCi2, and 5 mM phenyimethyisuifonyl fluoride) 
and subjected to a kinase assay with MBP (Myelin Basic Protein) 
used as an exogenous substrate [-32P]ATP and PPl (1 pM) or 
PP2 (1 pM), where indicated. After a 15-min incubation at 4°C in 
20 pi of the same buffer containing 4 pCi [-32P]ATP diluted with 
uniabeied ATP to a finai concentration of 26 pmoi ATP/sampie 
and 50 pM MBP, the reactions were stopped by the addition of 
reduced Laemmii buffer, and the products were heated at 100°C 
for 5 min. The radiolabeled RET and MBP proteins were resolved 
by SDS-PAGE and visualized by autoradiography. The intensity of 
the bands corresponding to autophosphorylated RET and 
phosphoryiated MBP was quantified by Phosphorlmager 
(Molecular Dynamics) analysis and expressed as the fold
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Increase relative to unstimuiated wiid-type RET. Control 
reactions in which RET immunoprecipitates were omitted showed 
no MBP phosphorylation (data not shown). Immunoprécipitation 
of equai amounts of RET was verified by anti-RET Western 
blotting and the quantity measured using 1251-iabeied protein A. 
The intensity of the bands corresponding to RET was quantified 
by Phosphorlmager (Molecular Dynamics) analysis.
2.11 d13-suc1 capture and immunoblotting
The Frs2 protein was isolated from cell lysates by incubating 
equai amounts of protein with pl3sucl-agarose (Oncogene 
Science) for 3 h at 4°C. P13sucl-agarose-captured proteins were 
washed three times with the above mentioned lysis buffer and 
boiled In Laemmii buffer for 5 min before electrophoresis. 
Captured proteins were subjected to 8% SDS-polyacryiamide 
gel, under reducing conditions, transferred to a nitrocellulose 
membrane (Miiiipore Co., Bedford, MA) and immunobiotted with 
an anti-Ptyr antiboby (UBI). The identity of phosphoryiated 
bands was further confirmed by subsequently re-probing with 
anti-RET and anti-Shp2 rabbit poiycionai antibodies (Santa Cruz 
Biotechnology).
2.12 Src kinase assav
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To determine Src activation, c-Src was assayed for its ability to 
undergo autophosphoryiation and phosphoryiate a synthetic 
Cdc2 peptide, as follow: Src was immunoprecipitated with anti- 
Src (clone G D ll UBI) antibody from PLCLB-soiubiiised ceil 
extracts as described (Borreiio et al., 1996). Src activity was 
assayed according to Cheng et ai. (Cheng et al., 1992) using the 
Src tyrosine kinase family-specific Cdc2 peptide substrate 
(Upstate Biotech-UBI). Immunoprecipitated anti-Src, prepared as 
described above, were incubated in 40|xi of Src kinase reaction 
buffer (lOOmM Tris-HCi, pH 7.4, 0.2mM EGTA, 250mM Na3V03, 
40mM Mg (Ac) lOpi of cdc2 peptide (Upstate Biotech-UBI), 5 pi of 
cold ATP (25pM), and 2.5pCi of [y-32P]ATP. After 15 min of 
incubation at 30°C, reactions were terminated by the addition of 
20 pi of 40% trichloroacetic acid and incubated for an additional 
5 min at room temperature. Aiiquots were subsequently blotted 
on to p81 phosphoceiiuiose paper (Upstate Biotech-UBI). The 
p81 phosphoceiiuiose paper was washed three times (5 
min/wash) with 0.75% phosphoric acid and once with acetone at 
room temperature and the radiolabeled Src kinase substrate was 
counted in a liquid scintillation counter.
2.13 DNA extraction
2.13.1 From ES cells
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The lysis buffer (lOOmM Tris Hci pH 8.5, 0.5M EDTA, 10% 
SDS, 5M NaCI, 20mg/mi Proteinase K) is added directly to the 
ceiis. Lysis of the ceiis was carried out at 37°C overnight with 
agitation.
To precipitate the DNA; one volume of isopropanol was added to 
the lysate and the samples were mixed or swirled until 
precipitation was complete ( about 10-20 min ).
The DNA was then recovered by lifting the aggregated 
precipitate from the solution using a disposable yellow tip. 
Excess liquid was dabbed off and the DNA was placed In a pre­
labelled Eppendorf tube containing, depending on the size of the 
precipitate, 20 to 500ul to lOmM Tris HCi, O.lmM EDTA, pH 7.5.
2.13.2 DNA from Tail Biopsies
Tails were removed into polypropylene microfuge tube and 0.5 
ml DNA digestion buffer (50mM Tris-HCi pH 8.0, lOOmM EDTA 
pH 8.0, lOOmM NaCI, 1% SDS, proteinase K 0.5mg/mi) added 
prior to incubation overnight at 50-55°C with gentle shaking.
To extract DNA, 0.7mi neutralized phenoi/chloroform/isoamyi 
alcohol (25:24:1) was added and spun in a microcentrifuge at 
top speed for 5 minutes before transferring 0.5 mi of the upper 
phase to a new microcentrifuge tube.
1 ml 100% ethanol at room temperature was added and inverted 
(using a clinical rotator) until a DNA precipitate formed
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(approximately 1 minute). The tube content was then spun in a 
microcentrifuge for 5 minutes and the supernatant was removed 
and discarded carefully. 0.5-lm i 70% ethanoi (-20°C) was then 
added and inverted several times before spinning in 
microcentrifuge for 5 minutes in order to carefully remove and 
discard the supernatant.
The tubes were then spun to remove the last drops of ethanol 
solution with a 25pi capillary tube. The peiiet was air dried at 
room temperature and then 100-200pi TE buffer was added 
before incubation at 65 °C for 15 minutes to resuspend DNA.
2.14 Southern blot anaivsis
For Southerns, 5-10 pg of genomic DNA was digested with the 
appropriate enzyme and run on 0.7% agarose gels in 0.5X TBE. 
DNA was transferred to a nylon membrane (Hybond-N, 
Amersham Int., UK) and subsequently hybridized with an [a- 
32P]dATP random-primed-iabeiied probe consisting of a PCR 
fragment from the RET coding region. Hybridization was done in 
6X SSC (IX  SSC is 0.15 M NaCi, 15 mM Sodium-Citrate, pH 7.0), 
0.1% SDS, 250 mg/mi hering sperm DNA and 50% formamide, 
at 42°C overnight. After hybridization, membranes were washed 
with:
IX, 15 minutes, room temperature, 2X SSPE/0.1% SDS
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IX, 30 minutes, room temperature, O.IX SSPE/0.1% SDS
IX, 30 minutes, 37°, O.IX SSPE/0.1% SDS
2X, 30 minutes, 68°, O.IX SSPE/0.1% SDS
Membranes were then exposed to a autoradiographic fiim for 96
hr.
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3. FUNCTIONAL ANALYSIS OF CYS MUTANTS ASSOCIATED BOTH 
WITH MEN2A AND HSCR DISEASE
3.1 Introduction
In rare famiiies, HSCR and MEN2A or FMTC can co-occur 
because of the same RET mutation (Attie et ai, 1995; Muiiigan et ai, 
1994). These combined phenotypes are generaiiy associated with a 
cysteine to arginine substitution in exon 10 of RET, especially at 
position 609, 618 and 620. Recent evidence has estabiished that the 
great majority of these mutated RET proteins transi oca te to the cell 
surface with iow efficiency (Ito et ai, 1997; Cariomagno et al, 1997; 
Chappius-Flament et al, 1998; Takahashi et a, 1999) and therefore 
phosphoryiated RET dimers accumulate within intracelluiar 
endosomai compartments (Ito  et al, 1997; Cariomagno et al, 1997; 
Chappius-Flament et al, 1998; Takahashi et ai, 1999 and our 
unpublished resuits). As a consequence, an insufficient amount of the 
mature RET receptor is availabie; a deficiency which compromises 
the correct deveiopment of the enteric nervous system. On the other 
hand, this aberrant distribution of the cysteine mutated RET receptor 
is stiii constitutively activated, and does not impair mitogenic 
signalling in the thyroid/adrenal glands, thus leading to hyperplasia 
or tumour formation.
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Dimerization of the RET receptor, either due to the presence of 
cysteine mutations or to the binding of its ligand, results in 
autophosphoryiation of intraceiiuiar tyrosine residues and creation of 
docking sites for a number of SH2-containing signal transduction 
molecules. These include GRB7 and GRBIO, phospholipase Cy (PLCy), 
SHC, GRB2, Enigma and FRS2 (Arighi et ai, 1997; Alberti et al, 1998; 
Soler et al, 1999; Asai et al, 1995) . Phosphatidyl 3 ' -kinase (PI3K) 
(Soier et al, 1999; Segouffin-Cariou and Billaud, 2000) has also been 
implicated in RET-mediated cell proliferation, survivai and motiiity 
(Marte and Downward, 1997). Recent works have reported that Src 
activity is necessary for the neuronai survival mediated by GDNF 
famiiy iigands mediated (Encinas et ai, 2001) and is required for the 
recruitment of RET to iipid rafts (Paratcha et al, 2001). I t  is weii 
accepted that proteins can trigger different signaiiing according to 
their cellular compartmentalisation. I here have attempted to dissect 
the signaiing pathways driven by a misiocaiised HSCR/MEN2A 
associated mutation (RETC^^°R) from the ones driven by the typicai 
MEN2A associated mutation (RETC^ '^^R) correctly expressed at the 
cell surface. This was done in order to estabiish the key events in 
RET mediated signaiing that predispose for HRSC disease in patients 
carrying the C620R substitution.
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3.2 Anaivsis of RETC620R and RETC634R localisation bv confocai 
microscopy
To compare the functional cosequences of mutations affecting 
the cysteine rich domain of RET, we introduced individual mutations 
by substituting cysteines 620 and 634 for an arginine in the cDNA 
coding for the short RET isoform. Lysates prepared from NIH3T3 ceils 
stably expressing the RET cysteine mutants were immunoprecipitated 
with an anti-RET serum and the resulting immunocomplexes were 
analysed by SDS-polyacrylamide gel electrophoresis. Western 
blotting of these samples with an anti-RET poiycionai antibody 
revealed two products of 140 kDa and 160 kDa, in whereas
in the ret^®^°  ^ mutant, the 160 kDa product was almost 
undetectable. Probing the same filte r with an anti-phosphotyrosine 
monoclonal antibody revealed that the 140 kDa product, 
corresponding to the partially glycosylated form of RET was 
phosphoryiated in ret^®^°  ^mutants whereas in ret ®^^ '^ '^  mutants, the 
most phosphoryiated band corresponded to the 160 kDa product (Fig 
1). These results confirmed previous data which suggested that the 
Cys-620 mutation results in a decrease of the level of RET at the cell 
surface. (Ito  et al, 1997; Cariomagno et al, 1997; Chappius-Flament 
et al, 1998; Takahashi et a, 1999 and our unpublished results).
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To further verify these findings, NIH3T3 ceiis expressing 
RETC62or qp p^ j^C634r ghort isoform, were also examined by 
immunofluorescence confocai microscopy using two different anti- 
RET polyclonal antibodies, one specific for the carboxy-terminal of 
RET and the other for the extracellular domain. The carboxy-terminai 
specific antibody detected the presence of both mutant receptors 
within intraceiiuiar compartments (Fig 1, green staining). Signal was 
particularly intense in perinuclear regions, suggesting a prevailing 
localisation in the endoplasmic reticulum. Furthermore, the C634R 
mutant receptor but not C620R, was localised at the cell surface, as 
revealed by surface staining obtained with the extra cellular specific 
antibody in Fig 1, red staining.
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Fîg. 1 mutant receptor, but not is iocalised a t the
cell surface. Cell lysates from untrasfected and RET^ 634R p^^jC620R 
transfected NIH3T3 cells were immunoprecipitated with anti-RET, 
subjected to SDS-PAGE and subsequently blotted with anti-RET and 
anti-Ptyr antibodies. The clones were also examined by
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immunofluorescence confocai microscopy. For surface localisation, 
ceils were incubated at 4°C with anti-RET extraceiluiar specific 
antibody. They were then fixed, permeabiiised and doubie stained 
with the carboxy-terminai specific antibody to reveai the intraceiiuiar 
distribution of the receptor. Note that RET^ 634R ^nutant receptor but 
not RET^®^°^ is localised at the cell surface, as revealed by surface 
staining obtained with the extraceiluiar specific antibody (red 
staining). Staining with the carboxy-terminus specific antibody 
detects the presence of both mutant receptors within intraceiiuiar 
compartments (green staining). Bar: 50 pm.
3.3 Different morohoiocicai features of ret^^^°^ and ret^^^"^^ 
transfected ceiis
RETC62or expressing ceiis examined by phase-contrast 
microscopy showed a phenotype simiiar to that of NIH3T3 
fibrobiasts, whereas ret^^^"^*^ expressing ceiis exhibited a bright, 
rounded morphology with very elongated processes. To better 
characterise the cytoskeletai changes associated to the expression of 
RETC62or and RET^® '^^  ^ we performed immunofluorescence analysis 
with FITC-iabeiied phaiioidin and vincuiin antibodies in order to 
respectively examine fiiamentous actin (F-actin) and focai contacts. 
Cells were double stained with anti-RET and phaiioidin or anti-RET
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and anti-vinculin. positive ceiis, and to a higher extent RET-
negative NIH3T3 ceiis (asterisks in fig 2A), showed a typical 
elongated fibroblastic shape and well organised actin stress fibers 
parallel to the long axis of the ceii and spread throughout the ceii 
body (Fig. 2A). The pattern of vincuiin staining indicated a peripheral 
positivity reminiscent of focai adhesion complexes (Fig. 2B), as if 
RETC62or expression in NIH3T3 fibrobiasts could scarcely affect their 
morphology. In contrast, ret^®^ '^ '^  positive ceiis had characteristic 
features of transformed ceiis. They did not possess well-defined F- 
actin stress fibers, but rather presented corticai bundies of actin 
filaments visible as linear iines aiong the margin of the ceils (Fig. 
2A). Vincuiin staining of ret ®^^ "^  ^ was localised to the perinuciear 
regions and almost absent in the ceii periphery, where a significant 
reduction in focai contacts was observed (Fig. 2B). These resuits 
highiighted important structural differences between ret^®^ °  ^ and 
RETC534r expressing ceiis that may aiso affect ceii motiiity.
87
Funcüona/ an/ys/s of Cys mufanfs
RETC634R
REU
# 0
RETC620R
RET I  ACTIN
*  I  ..
B
RETC634R
RETC620R
Fig.2
Fig. 2 expression in NIH3T3 cells induces changes in
ceii architecture. (A ) RET and actin distribution in and
RET^62or expressing cells. To analyse stress fibers and actin 
organization, transfected cells were double stained with anti-RET
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(red) and FITC-conjugated Phaiioidin (actin, green). (B ) RET and
vincuiin distribution in and expressing ceiis. In
order to analyse focal contacts, transfected cells were double stained 
with anti-RET (red) and anti-vincuiin (green) antibodies. The images 
were anaiysed by confocai microscopy. The asterisks indicate
untrasfected NIH3T3 cells not expressing the RET mutants. Bar: 50 
pm.
3.4 Different mobiiity of ret^^^or expressing cells
To assess differences in the motility between the two cell types, 
an in vitro wound repair modei (Sato et ai, 1988) was used. Ceiis 
including the parental line were wounded, ceil culture medium 
removed and the monoiayers incubated. After 15 h from wounding, 
NIH3T3 un transfected cells and to a lesser extent ret ®^^ ®'^  
expressing ceils, showed no significant migratory potentiai (Fig. 2C). 
In contrast, C634R expressing ceiis demonstrated extensive 
migration into the denuded area (Fig. 2C).
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Fig. 2 expression in NIH3T3 cells induces changes in cell
architecture. (C) expressing cells show a consistent motile
potential. Monolayers of untrasfected NIH3T3 cells, and
REJC620R transfected cells were wounded and cultured in presence of 
serum for 15 hours. Cell migration into the denuded area was 
evaluated at 0 and 15 hours with a iight microscope equipped with 
phase-contrast optics (original magnification 200X).
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3.5  and recruitment of signaling molecules
Focus forming assays on NIH3T3 fibroblasts demonstrated 
that displayed a transforming activity although lower than
the activity displayed by (Fig 3 upper panel). I t  was then
tempting to speculate that both the p l40  precursor and p l60  
mature forms of RET, when phosphorylated and dimerized, could 
transduce mitogenic signalling in spite of their different localization: 
the ER for ret^®^®'^ and both the ER and the surface membrane for 
RETC^ 34R_ immunoblot analysis with anti-RET specific antibodies, 
confirmed that ret^®^°^ transfected clones almost exclusively 
expressed the p l40  band, corresponding to the partially 
glycosylated form of RET. In order to explain the transforming 
activity of RET^^^or  ^ we investigated its ability to transduce 
mitogenic signals. In particular, we studied whether both RET 
carrying the C620R and C634R mutation were able to bind to the 
She adapter protein and PLCyas previously demonstrated for 
RETC634R (Carlomagno e ta l., 1997; Chappuis-Flament e ta l., 1998). 
Cell lysates from ret^^^or |^ -^pC634R transfected NIH3T3 cells 
were immunoprecipitated with anti-Shc or anti-RET antibodies and 
subsequently blotted with anti-Ptyr antibodies. Both the precursor 
and mature forms of RET were co-immunoprecipitated with She 
phosphorylated proteins as already demonstrated for other RET 
mutants by Carlomagno et al. (Carlomagno et al, 1997) (Fig. 3
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lower panel). The possibility that RET mutant precursors interacted 
with She in intracellular endosomal compartments is supported by 
the presence of She proteins in the plasma membrane and 
endocytic structures as previously shown by others (Lotti et al, 
1996).
Analogously, immunoprécipitations were carried out using anti-PLCy 
and anti-RET antibodies and then blotted with anti-Ptyr or anti-RET 
antibodies. In ret^®34r transfected cells, tyrosine phosphorylated 
PLCy was predominantly associated with the p l60  form of RET. In 
p^ g-|-c620R transfected cells, most of the phosphorylated PLCy protein 
was recovered associated with the p l40  partially glycosylated form 
of RET (data not shown).
Therefore, intracellularly retained ret^^^or proteins strongly bind 
phosphorylated She and PLCy, thus confirming their ability to induce 
mitogenic pathways driven by these two proteins independent of 
their cellular localization.
I t  has been recently demonstrated that RET activated by 
GDNF or by classical MEN 2A mutations (such as C634Y or C634R) 
interacts with Frs2 and directly complexes with Shp2 tyrosine 
phosphatases (Califano et al, 2000; Kurokawa et al, 2001). Frs2 
has been shown to be involved in neuronal signaling, in particular it 
regulates cell cycle arrest and neuronal differentiation (Rabin et al, 
1993). Interestingly, as for the TRKA receptor, (Meakin et al.
92
Functional aniysis o f Cys mutants
1999), the Frs2 binding site on RET, to tyrosine 1062, is 
concomitantly the binding site for She (Kurokawa et al, 2001) and it 
has also been demonstrated that competition between SHC and 
FRS2 at the Tyr-1062 binding site, can in part be involved in the 
switch between cell cycle progression/mitogenesis and cell cycle 
arrest/differentiation .
We therefore investigated whether the ret^®34r p^ gycezoR 
isoforms interacted with the Frs2 signal transducer and Shp2. Cell 
lysates from ret^®34r ^gycezoR transfected cells were subjected 
to immunoprécipitation using agarose conjugated with the p l3-suc 
protein, which specifically binds Frs2 and indirectly Shp2. The 
complex has been examined in immunoblot analysis using anti-Ptyr, 
and then serially reprobed with anti-RET, anti-Frs2 and anti-Shp2 
antibodies (Fig. 3 lower panel). In immunoblot experiments, 
coimmunoprecipitation of all the isoforms of ret^®34r gp^j |^^jC62or 
with Frs2 and Shp2 phosphoproteins was detected. Therefore, the 
partially glycosylated form of RET carrying the C620R mutation, as 
well as RET with the C634R mutation is able to interact with Frs2. 
This supports the possibility that the intraceliular membrane 
compartment can also transduce RET-Frs2 signaling.
Various data support the idea that despite the lack of an 
enzymatic kinase domain, Crk plays a crucial role in growth factor- 
stimulated signal transduction and regulation of the act in
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cytoskeleton (Ishiki et al, 1997; Nakashima et al, 1999). Tyrosine- 
phosphorylated proteins known to be associated with actin stress 
fibers in adhesion foci, such as plSOCas or Paxillin, have been 
shown to interact with the SH2 domain of Crk. We investigated 
whether ret^^34R g p j p^^jC620R recruited Crk in the respective 
transformed cells, which exhibited differences in the organisation of 
their focal adhesions (Fig 2). Phosphorylated ret^^34r g p j |^gjC620R 
were detected in Crk immunoprecipitates from both transfected cell 
types (Fig 3 lower panel). Therefore, since Crk adapter protein can 
bind and possibly trigger specific signaling from both RET mutants, 
the observed differences in focal adhesion complexes found in the 
transformed cells, could suggest the existence of distinct Crk roles, 
possibly involved in different signalling pathways and cellular 
processes.
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Fig. 3 and recruitment o f signaling molecules.
RET transforming activity was assayed transfecting NIH3T3 cells 
with and and the number of foci counted. The
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results are of four independent experiments, and expressed as the 
number of foci per micrograms of transfected DNA (Upper panels). 
Cell lysates from untrasfected and and transfected
NIH3T3 cells were immunoprecipitated with anti-Shc or anti-RET 
subjected to SDS-PAGE and subsequently blotted with anti-Ptyr 
antibodies. Cell lysates were also subjected to immunoprécipitation 
using both anti-RET and agarose conjugated with the pl3-suc 
protein, which specifically binds Frs2 and indirectly Shp2. pl3suc 
immunoprecomplexes were separated on SDS-PAGE, analysed in 
Western blotting with anti-Ptyr anibodies and then serially re­
probed with anti-RET, antl-Frs2 and anti-Shp2 antibodies. Cells 
lysates were also subjected to immunoprécipitation with anti-Crk 
antibodies, subjected to SDS-PAGE and phosphorylated bands 
visualised with anti-Ptyr antibodies. RET immunoprecipitates were 
analysed to asses RET protein phosphorylation in each cell type 
(lower panels).
3.6 High Src activitv in RETMEN 2A expressing cells
Since Src has been implicated in RET mediated mitogenic 
activity and is found to co-im mu noprecipitate in vivo with activated 
RET (Melillo et al, 1999), we evaluated whether the mutants, 
RET^ 634R gnd RET^®^°^ were able to interact with Src. We 
immunoprecipitated Src kinase using specific antibodies and 
analysed the presence of RET mutants using RET specific 
antibodies. Both the mutants were present in Src
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immunoprecipitates (data not shown). Since the Src protein can be 
phosphorylated on tyrosine residues in an inactive or active state 
(Cooper and Howell, 1993; Nada et al, 1991) we used an in vitro 
kinase assay to establish the effects of C634R and C620R on Src 
activity. Src activity was measured by the capacity of Src 
immunoprecipitates from untrasfected NIH3T3, and
RETC62or expressing cells to tyrosine phosphorylate the synthetic 
Src specific cdc2 peptide (Church et al, 1994). RETC634R 
expressing cells showed a pronounced kinase activity, 3 to 4-fold 
higher than the one found in ret^^^or ^qIIs, whose level correlated 
with that of normal parental NIH3T3 cells (Fig. 4).
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Fig. 4 High Src activity in RETC634R expressing cells. Cell lysates 
were prepared from serum starved cells and were 
immunoprecipitated with anti-Src antibodies. Src 
immunoprecipitates were subjected to an in vitro kinase assay 
using the the synthetic Src specific cdc2 peptide as a substrate. 
Kinase activity was evaluated by counting the cpm incorporated by 
radiolabelled cdc2. The results of four independent experiments are 
expressed as fold of induction with respect to untrasfected NIH3T3 
cells. Data represent the means + /- SD of the values, (upper
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panel). Src immunoprecipitates were analysed by Western blotting 
with an anti-Src antibody to control protein expression in 
untrasfected NIH3T3 cells, and transfected cells
(bottom panel).
Since RET is physiologically expressed in cells of 
neuroectodermic origin, the human neuroectodermic SK-N-MC cell 
line represents a model in which to study RET signaling. The SK-N- 
MC cell line was stably transfected with RET wild type, RET^® '^^  ^
^gyC620R^ P^ EjC609w g^id RET^ ^®^ '’ and RET expression and
phosphorylation checked. We then investigated whether, in this 
more physiological context, differences in activating Src were 
detected between the RET mutants, as observed in NIH3T3 cells.
Src activity is regulated by tyrosine phosphorylation at two 
sites with opposing effects. Phosphorylation of Tyr416 in the 
activation loop of the kinase domain upregulates the enzyme, 
whereas phosphorylation of Tyr527 renders the enzyme less active 
(Hunter, 1987; Nada et al, 1991). An antibody that detects Src 
only when activated by phosphorylation at Tyr416 was used in 
Western blot experiments. I t  was demonstrated that Src 
phosphorylation was present only when proteins were extracted 
from RET^ ®^ "^  ^ transfected cells (data not shown). In fact, as
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observed in NIH3T3 cells expressing the different Cysteine RET 
mutants, Src seemed to be inactive in ret^^^or transfected SK-N- 
MC cells. Moreover, the Tyr416 phopshorylation was also absent 
when Src phosphorylation was assessed In the RET^^°^^ and 
RETS765a mutants, thus again suggesting that Src activity might 
indeed play a crucial role, which is probably impaired in 
Hirschsprung disease.
3.7 High d38 MAP kinase phosohorvlation in RETMEN 2A expressing 
cells
Previous studies have demonstrated that RET stimulates Jun N- 
terminal kinase (JNK) and extracellular signal-regulated kinase 
(ERK) signaling (Chiariello et al, 1998). We analysed the kinase 
activity of p44/p42, JNK and p38 MAPKs. We did not find significant 
differences in the activation level of ERKl, ERK2 and JNK in
RE1-C634R and re t^ ^ 2or expressing cells but an higher
phosphorylation of p38 in cells was clearly detected (Fig.
5). This activity could be related to cytoskeletal rearrangements 
and/or the motility we found in expressing cells. In fact,
the p38 pathway is involved in cell migration and organisation of
the actin cytoskeleton (Matsumoto et al, 1999). This could be
achieved in virtue of ability that p38 has in controlling and
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coordinating cellular activities such as gene transcription and 
adhesion (Hall et al, 1998). Moreover, consistent with our data, the 
expression of the v-Src oncoprotein has been shown to strongly 
stimulate p38-MAPK in different cell types (Turkson et al, 1999; Lee 
et al, 1999). However, little is still known about the contribution of 
Src family kinases to the signaling pathways which link RET to p38- 
MAP activation.
p h o s p h o - p 38
p 3 8
Fig.S
Fig. 5 High p38 MAP kinase phosphorylation in RETC634R 
expressing cells. Total cell lysates from transfected and untrasfected 
NIH3T3 cells, serum starved for 20 hours, were subjected to SDS-
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PAGE and inn mu noblotted with anti-p38 (top) and anti-phospho p38 
antibodies (bottom). Where indicated, NIH3T3 cells after starvation 
were treated with UV irradiation. Similar results were obtained 
performing three independent experiments.
3.8 GDNF induces scattering of SK-N-MC neuroepithelioma cells 
expressing but not SK-N-MC cells expressing Hirschsprung
associated RET mutations.
In order to test the effects of the expression of RET Cys 
mutations In a more physiological context, since RET is expressed in 
cells of neuroectodermal origin, the human neuroectodermal SK-N- 
MC cell line was stably transfected with RET wild type, C634R, 
C620R, C609R, and S765P and RET expression and phosphorylation 
was checked.
Ligand-induced activation of RET In SK-N-MC neuroepithelioma 
cells stably transfected to express RET wild type, generates a 
"scattering" response, as demonstrated by van Puijenbroek (van 
Puijenbroek e ta l, 1997). In parental SK-N-MC cells, scattering is also 
induced by treatment with bFGF (van Puijenbroek et al, 1997). Cell 
scattering is characterised by several morphological changes such as 
the loss of epithelial features and cell dissociation with consequent 
individual movement. In order to determine the ability of RET 
cysteine mutants to respond to GDNF, we took advantage of this
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system. SK-N-MC cells stably transfected to express RET wild type, 
RETC634R^  RET^ ®2or^  P^ -^|-c609w RET^^ssp therefore cultured and
stimulated with GDNF. GDNF induced-scattering was clearly visible 
for those clones expressing RET wild type and but not for all
the other RET mutants, RET^ ^^ OR^  p^ 2yC609w g^d RET^^esp (pjg 5 ), that 
are associated with Hirschsprung's disease. The scattering effect was 
associated with an increase in RET phosphorylation, assessed when 
RET was immunoprecipitated and its tyrosine phosphorylation 
checked by anti-Ptyr Western blotting. These results clearly 
demonstrated that GDNF induced a considerable enhancement of 
RETC634R autophosphorylation together with a scattering effect, 
despite its constitutive activation. On the contrary all RET mutants 
associated with Hirschsprung's disease did not respond to GDNF 
since neither an increase in the levels of RET autophosphorylation 
nor a scattering effect was detectable. This is an interesting result 
since it has been demonstrated that GDNF promotes the migration of 
enteric neural crest-derived cells and may be important for driving 
neural crest cell migration along the gut, preventing them from 
straying within the mesentery and in promoting axon outgrowth 
(Young et al, 2001). Consistent with this, the RET mutants 
associated with Hirschsprung's disorders analysed were unable to 
respond to GDNF treatment, which should result in cell dissociation
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and consequent individual movement.
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Fig. 6 GDNF induces scattering o f SK-N-MC neuroepithelioma cells 
expressing but not o f SK-N-MC cells expressing
Hirschsprung associated RET mutations. SK-N-MC cells stably 
transfected to express RET wild type, ret^^24r f^pjC620R RET^^es
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were cultured after starvation in the presence or absence of 50nM 
GDNF and, the scattering effect observed.
3.9 Discussion
As a paradox, sonne cysteine mutations of RET such as the 
RET Cys®^° substitution are oncogenic in neuroendocrine cells and 
responsible for MEN2A and FMTC, but at the same time, they can 
impair enteric neuronal development leading to HSCR disease. In 
order to address the question of why certain substitutions 
predispose to HSCR disease, we compared the biological and 
biochemical features of cells transfected with RET carrying either 
the Cys®^° or the mutation that is commonly found in MEN2A
and FMTC patients, but does not affect neuronal development.
In agreement with previously reported biochemical results, 
our confocal microscopy analysis of RET localisation demonstrated 
that ret^®2or primarily accumulates in intracellular endosomal 
compartments and is almost absent at the cell surface. In contrast, 
RETC634R proteins appeared to be localised at the cell surface as well 
as intracellularly. Moreover, although differently localised within 
cells, the ret^^^or grid the mutants activate similar
mitogenic pathways but display characteristic morphological 
features, ret^^ "^^  ^ expression drives cellular modifications, including
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cell rounding and increased motility due to adhesion loss and 
disruption of the actin cytoskeleton. These changes are not 
associated with ret^^^or transformation of NIH3T3 cells. The 
expression pattern of ret ®^^ '^^  and the associated morphological 
features are accompanied by low levels of Src kinase activity, 
whereas ret ®^^ '^ '^  drives a sustained activation of this signalling 
molecule.
As the induction of RET-mediated Src activity requires RET 
localisation to lipid rafts (Tansey et al, 2000), our results support 
the idea that RET mediated activation of Src signaling pathways is 
less efficient in those mutants retained within the ER. Although no 
data on any RET variant localisation in lipid rafts has been reported 
yet, our findings are in line with previously reported data 
demonstrating that cellular Src as well as v-Src, was associated 
with perinuclear endosomal membranes in its inactive state (David- 
Pfeuty and Nouvian-Dooghe, 1990) and upon activation, it 
complexed with actin and translocated to focal adhesions at the cell 
periphery.
From a functional point of view, it is well accepted that Src is 
a co-ordinator of specific events that control cellular morphology 
that give rise to an altered growth pattern, cell rounding and 
increased motility as a consequence of adhesion loss and disruption
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of the actin cytoskeleton, as clearly dennonstrated both for 
transformed fibroblasts and neuronal cells. Expression of activated 
Src in fibroblasts alters cell morphology and reduces cell adhesion 
to the extracellular matrix (Brown et al, 1996). Src associates 
directly with the Focal Adhesion Kinase (FAK) and localises to focal 
complexes where it stimulates focal contact turnover (Fincham et 
al, 2000). The consequent loosening of cellular adhesion strength 
allows cells to easily detach and move (Fincham et al, 2000). 
Cultured neurones lacking either Src or Fyn exhibit defects in 
neurite outgrowth in response to cell adhesion molecules and mice 
lacking Src and Fyn kinases exhibit defects in axon guidance and 
fasciculation (Beggs et al, 1994); specifically, Src activity results 
concentrated In growth cones, where it affects the regulation of 
actin dynamics in response to extracellular signals (Lipfert et al, 
1992).
The RET^ ^^ oR variant, when expressed in the neuroectodermic 
SK-N-MC cell line, together with the inability to induce Src activity, 
also failed to respond to GDNF stimulation. Addition of GDNF 
neither increased ret^®^ °^  and ret^^ °®'^  phosphorylation levels nor 
induce cell scattering, since their intracellular location impeded their 
interaction with the membrane associated GDNF/coreceptor 
complex. GDNF promotes the migration of enteric neural crest- 
derived cells and it is important for driving neural crest cell
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migration along the gut, in preventing them from straying within 
the mesentery and in promoting axon outgrowth (Young et al, 
2001).
In conclusion, here we propose a model in which the 
mislocalised ret^^^or mutant, although able to trigger mitogenic 
signaiing even if retained within intracellular compartments, fails in 
activating Src and responding to GDNF. This thus compromises 
cellular morphological modifications essential for neuroenteric 
precursor development and movement, leading to HSRC disease.
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4. PPl INHIBITOR INDUCES DEGRADATION OF RETMEN2A AND 
RETMEN2B ONCOPROTEINS THROUGH PROTEOSOMAL 
TARGETING
4.1 Introduction
The study of the activity of Src in RET transfornned cells has 
been hampered by the lack of specific inhibitors. PPl, which is 
thought to be a Src-family-selective small inhibitor, was shown to 
have interesting effects on RET expressing cells. The knowledge of 
the availability of Inhibitors specific for RET oncoproteins could 
provide new tools capable of highlighting the physiologically and 
pathologically activated pathways involved and help in developing 
new therapeutic strategies for RET-associated diseases. The 
inhibition of tyrosine kinase activity by small, cell-permeable 
molecules is a promising approach to target oncoproteins and has 
already reached clinical application for ErbB/HER subgroup of 
receptors (Mendelsohn et al, 2000; Dancey et al, 2001). 
Carlomagno et al. have very recently demonstrated that the 
pyrazolo-pyrimidine PPl blocks tumorigenesis induced by RET/PTC 
cytoplasmic oncogenes by inhibiting RET enzymatic activity and its 
transforming effects (Carlomagno et al, 2002). We have further 
explored the mechanism of action of the inhibitor, specifically 
showing that PPl abrogates the cellular morphological
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modifications induced by the expression of different cytoplasmic or 
membrane-bound RET oncoproteins in NIH3T3 cells, restoring the 
characteristic fibroblast actin organization and focal adhesion 
formation. We also present evidence that, along with the inhibition 
of tyrosine phosphorylation, PPl induces proteosomal destruction 
of activated receptors. In fact, in the presence of the inhibitor the 
receptors are rapidly targeted to the degradative pathway and the 
intracellular destruction of ubiquitinated RET oncoproteins results 
accelerated. Taken together, our results suggest that PPl 
treatment may represent a promising new strategy to selectively 
target RET oncogenic products for destruction and could be used 
to develop new therapeutic techniques for medullary thyroid 
cancer therapy, which presently responds very poorly to 
chemotherapeutic agents.
4.2 PPl reverts the transformed moroholoov and affects motilitv 
of cells expressing RET/MEN2 oncoproteins.
In agreement with what has been already described by 
Carlomagno et al. (Carlomagno et al, 2002), PPl evidently effects 
the morphology of fibroblasts expressing RET carrying the C634R 
and M918T substitutions, which are the most important MEN2A
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and MEN2B associated mutations. These cells, examined by 
phase-contrast microscopy (Fig lA ), exhibited a bright, rounded 
morphology with elongated processes very different from the 
typical phenotype of parental NIH3T3 cells. In the presence of PPl 
at l|xM for 12 hours, they appear to revert their morphology, 
becoming similar to untransformed NIH3T3 fibroblasts. As 
expected, PPl exerted also clear effects on RET/PTC3 cell 
morphology as well. As control, parental NIH3T3 cells and NIH3T3 
expressing TRKA were also examined by phase-contrast 
microscopy, yet yhey did not show any significant change in their 
morphology upon PPl treatment (Fig. lA ).
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Fig 1: EfFects o f PPl on and RET/PTC3
transformed cells. (A ) PPl reverts the transformed morphology o f 
RE1^^34r^  PET^918t /^ET/PTCJ. NIH3T3 fibroblasts stably
transfected to express j  RET/PTC3 plated or not
in presence of 1 |iM PPl, were analysed 12 hours after plating by 
phase-contrast microscopy. TRKA-expressing and parental NIH3T3
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fibrobasts were used as controls and analysed like the other cell 
lines.
To further characterise the cytoskeletal rearrangements 
associated with the morphological changes observed in 
RET^918t gpjj RET/PTC3 expressing cells upon PPl treatment, 
immunofluorescence analysis was performed. Cells were double 
stained with RET and FITC-labelled phalloidin to examine filamentous 
actin (F-actin) (Fig. IB ). Cells expressing RET^® '^^  ^ |^£j M918t g ^ j 
RET/PTC3 treated with 1 jxM PPl exhibited a markedly greater 
amount of actin stress fibers well organised with a pattern similar to 
that seen for RET negative NIH3T3 cells (Fig. IB  upper panel), when 
compared to untreated cells. In contrast, parental NIH3T3 cells and 
NIH3T3 overexpressing TRKA did not show any significant 
morphological change upon PPl treatment (Fig. IB ). Moreover, PPl 
addition also drastically changed vinculin subcellular localisation in 
RETC634R^  RET'^ 918t gnd RET/PTC3 transformed fibroblasts (Fig. 1C). In 
fact, while in untreated cells we found a consistent cytoplasmic pool 
of vinculin, primarily in the perinuclear region, in PPl treated cells, a 
significant fraction of vinculin was seen at the cell periphery in 
punctuate structures reminiscent of focal adhesion plaques (Fig. 1C). 
Therefore, the addition of PPl induced actin stabilisation and
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formation of enlarged vinculin-positive focal adhesions, similar to the 
ones observed in parental NIH3T3 cells, thus reverting the 
transformed phenotype of RET/PTC3
fibroblasts. PPl had no effect on vinculin distribution in TRKA 
expressing cells.
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Fig 1: (B ) RET^^^ '^  ^and RET/PTC3 expression In NIH3T3 cells
Induces changes In actin distribution which are reverted by PPl. 
RET and actin distribution in NIH3T3, RET^^^^^ RET^^^^®\ RET/PTC3 
and TRKA expressing cells treated with PPl. Where indicated, 
transfected cells were plated in the presence of 1 iiM PPl and after 12
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hours from plating, fixed and double-stained with anti-RET antibody 
and FITC-conjugated phalloidin (actin). (C) PPl modify vinculln 
subcellular localisation In RET/PTC3 expressing
cells. To analyse focal contacts, transfected cells were plated in the 
absence or presence of 1 |iM PPl. After 12 hours from plating, they 
were fixed and double-stained with anti-RET and vinculin. Images 
were analysed using confocal microsccopy. Bar: 15 inm.
An m vitro wound repair model (Sato and Rifkin, 1988) was 
used to assess whether the architectural changes induced by PPl 
treatment, could also affect cell motility. Cells including parental 
NIH3T3 cells, were seeded and cultured until 50% confluence and 
then wounded, cell culture medium removed and the monolayers 
incubated. After 12 h from wounding, and
expressing cells demonstrated extensive migration into the denuded 
area (Fig. 2). In contrast, NIH3T3 untransfected cells showed no 
significant migratory potential (Fig. 2). When the same experiments 
were repeated with cells cultured for 12 hours with PPl, we observed 
that PPl-treatment affected the ability to move, of and
RET^918t expressing cells whereas the motility of parental NIH3T3 
cells was not affected (Fig. 2). This result provided new information 
on the effects of PPl on RET transformed cells.
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Fig 2: Motility o f untrasfected NIH3T3 ceils, and R£7^®'®^
expressing cells treated with PPl. Monolayers of untransfected NIH3T3 
cells, and ret^^^®^ expressing cells were wounded and cultured
in presence of serum. Where indicated, 1 \iM PPl was added for 12 
hours. Cells migration in the wound was evaluated at 0 and 12 hours 
after with a light microscope equipped with phase-contrast optics 
(original magnification 200x).
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4.3 PPl prevents GDNF mediated scattering of RET expressing 
SK-N-MC cells.
Ligand-induced activation of RET in SK-N-MC neuroepithelioma cells 
stably transfected to express RET wild type, generated a "scattering" 
response, as demonstrated by Van Puijenbroek (Van Puijenbroek et 
al, 1997). In parental SK-N-MC cells, scattering is also induced by 
bFGF treatment (Van Puijenbroek et al, 1997). Cell scattering is 
characterised by several morphological changes such as cellular 
loosening of epithelial features and cell dissociation with consequent 
individual movement. In order to determine the effects of PPl on RET 
receptor activity, we took advantage of this system and treated SK- 
N-MC cells stably transfected to express RET wild type and 
stimulated with GDNF and PPl. The inhibitor was not only able to 
inhibit GDNF induced scattering but it could also revert the scattering 
response when given after the morphological changes. I f  PPl is given 
to parental SK-N-MC cells in presence of bFGF, which promotes a 
scattering response, there are no significant effects. Thus PPl can 
specifically inhibit RET mediated scattering but not that induced by 
bFGF (Fig. 3).
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Fig 3: PPl prevents GDNF mediated scattering o f RET expressing SK- 
N-MC ceiis. SK-N-MC cells, stably transfected to express RET wild 
type, were se rum-starved and stimulated with GDNF orwith GDNF 
together with PPl. As controls, parental SK-N-MC cells were 
stimulated with bFGF which is known to promote scattering or with 
bFGF together with PPl.
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4.4 Inhibition o f RET oncoprotein in vitro kinase activity bv PPl 
and PP2
In order to evaluate RET in vitro kinase activity in the presence of 
the PPl inhibitor, RET wild type and the RET^ ®^ '^ '^ , re t'^^ is t 
RET/PTC3 mutants were transiently transfected into 293T cells and 
the synthesis of the correctly sized proteins was verified (data not 
shown). In vitro RET kinase activity was dramatically reduced when 
the assay was performed in the presence of PPl at a concentration of 
1 pM. As shown (Fig. 4 upper panel), both RET autophosphorylation 
activity and transphosphorylation of MBP was impaired. As a control, 
293T cells were also transiently transfected with a construct coding 
for the TRKA wild-type protein and enzymatic activity evaluated. In 
this case, no significant differences were found when the assay was 
performed in the presence or absence of PPl inhibitor (Fig. 4 upper 
panel). These results clearly demonstrated that PPl was able to 
strongly reduce the ability of RET to both auto- and trans- 
phosphorylate substrates, probably by specifically competing for the 
ATP binding site as already reported (Carlomagno et al, 2002). To 
further verify whether PPl could f it  within the RET ATP-binding 
domain, another inhibitor PP2, which has a chemical structure very 
similar to that of PPl (as shown in Figure 4), was used. PP2 mimiced 
the results obtained with PPl, reducing both RET
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autophosphorylation and the phosphorylation of MBP (Fig. 4 lower 
panel). In contrast, other tyrosine kinase inhibitors such as Genistein 
or Herbamycin, only partially affected RET enzymatic activity (data 
not shown and Carlomagno et al, 2002). Taken together, our results 
strongly suggest that PPl and PP2 have structures that specifically f it  
within the ATP binding domain of RET, thus preventing ATP binding.
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Fig 4: In vitro Immunocomplex RET kinase assay In presence of PP l. 
293 cells were transiently transfected to express RET^^ '^^ ,^ RET^^^®\ 
PTC3, and TRK. Protein extracts were immunoprecipitated with anti- 
RET and subjected to kinase assay with MBP as an exogenous
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substrate, [y-^^P]ATP and PPl (1]liM ) or [y-^^P]ATP. The radio-labelled 
RET and MBP proteins were resolved by SDS-PAGE and visualised by 
autoradiography. The intensity of the bands corresponding to 
autophosphorylated RET and phosphorylated MBP was quantified by 
Phosphorlmager analysis and expressed as the fold increase relative 
to unstimulated RET wild type. Data represent the mean of three 
different experiments.
4.5 PPl treatment of RETMEN2A and RETMEN2B-exDressina cells 
not onlv affects RET autophosohorvlation but induces RET 
oncoprotein degradation
To assess the effects of PPl in living cells, and ret ®^^ ®^
expressing cells were tested for RET expression and phosphorylation 
at various times. Parental and TRKA-overexpressing NIH3T3 cells 
were used as controls. Cells were incubated in the absence (-) or the 
presence of 1 pM PPl for 0, 3, 6, 12, 24, 48 and 72 hours prior to 
cell lysis. Tyrosine-phosphorylated proteins were detected by western 
blotting with anti-pTyr antibodies. As expected, PPl could 
dramatically reduce the amount of phosphorylated bands in anti-RET 
immunocomplexes or whole cell lysates (WCL) when visualised on a 
gel. RET phosphorylation already appeared reduced 3 hours after the 
addition of PPl and was observed to remain very low even after 72 
hours (Fig. 5A). Surprisingly, when we checked for equivalent protein 
loading, by re-probing the same blots with anti-RET antibodies, we
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discovered that the entire RET protein content of the cell decreased 
along the time course for both and ret ®^^ ®^  (Fig. 5A), but
no differences in alpha tubulin content was observed in these cells. 
Therefore, PPl was not only able to reduce RET phosphorylation, but 
unexpectedly, it was also able to cause a progressive loss of RET 
expression. The effect was specific for RET because PPl treatment 
was ineffective on TRKA-over-expressing fibroblasts (Fig. 5B). A 
progressive loss of RET expression was also observed for RET/PTC3 
as shown in Fig. 4B, though the protein level appears clearly reduced 
after 18 hours. The disappearance of the RET protein was also 
observed in western blotting experiments when ret ®^^ "^  ^and ret ^^ ^®^  
cells were treated with PP2 but not when the same cells were 
cultured in the presence of PP3 (a negative control of PP2 that is able 
to inhibit the activity of EGFR kinase), or in the presence of other 
tyrosine kinase inhibitors such as Genistein or Herbamycin (Fig. 5C). 
This result again indicated that as expected, both PPl and PP2 exert 
similar effects on the RET oncoproteins, since they share a common 
chemical structure. Interestingly, a significant decrease in the 
amount of RET protein, along with a decrease in its phosphorylation, 
was detected even when proteins extracted from TT-cells (a human 
medullary thyroid carcinoma cell line), were immunoprecipitated with 
anti-RET antibodies and western blot analysis was performed with
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anti-RET and anti-pTyr antibodies (Fig. 5D). As expected, in this 
case, the rate of RET protein degradation was slower than in NIH3T3 
cells overexpressing the oncoproteins.
A  IB : a .-*IiT  I1.-BET
PPl k K  
RETC63«.
REIM91fT
KET063Æ
REiMsirr
IB :
PPl 
TW,
B IB :
PPl
IB :
PPl h  
RET/PTC5
- 3 6 12 I t  34 36 4S 72 - 3 6 12 I t  34 36 4t72
IP :a.-EET
IP : ol-EET
W CL
W CL
iL -T iiirfn
- 3 6 12 I t  34 36 4 t 72 -  3 6 12 I t  34 36 4 t 72
mm m m -m t mm^mrn mm- # # # # # #  #W # # W CL
KETG634R. REIM91tT
■L^Tyr il-TRK
[ - 3 6 12 I t  34 36 4 t 72 - 3 6 12 I t  34 36 4 t 72
^ s s s s s s s s s s
IP : I1.-TRK
u.-«Tyr 0.-BET
3 6 12 I t  34 36 4 t 72 3 6 12 I t  34 36 4 t 72
mm «m , IP : 0.-BET
IP :
RETC63ffi.
RETC63flt
D
PPl
IP : il-SET
OrBET
- 34 4S 72 95
IB : itfT y r  
IB : 0.-BEI
# # » #
IB : iL-fTyr 
IB : il-B E I
IB : il-Ti
PPl
TW,
34 4S 72 96
Fig.5
124
PPl inhibitor induces degradation
Fig 5: Time course o f PPl treatment. (A ) The indicated cell lines 
were incubated in the absence (-) or presence of 1 jxM of PPl for the 
indicated time, prior to cells lysis. Anti-Ret immunocomplexes (Ip) or 
whole cell lysates (WCL) for or RET^ ®^ ®^  expressing
fibroblasts, were separated on reducing 7% SDS-PAGE and 
transferred to nitro-cellulose membranes. Upon incubation with anti- 
pTyr antibodies, tyrosine-phosphorylated proteins were detected by 
western blotting. After stripping, the amount of protein was verified 
by re-probing the same blots with anti-RET. Equal protein loading 
was also confirmed by western blot analysis using anti-tubulin 
antibody. (B ) For TRKA overexpressing cells, anti-TRK 
immunocomplexes (Ip) or whole cell lysates (data not shown) were 
also separated on reducing 7% SDS-PAGE and transferred to nitro­
cellulose membranes. Upon incubation with anti-pTyr antibodies,
tyrosine-phosphorylated proteins were detected by western blotting. 
Anti-TRK antibody was used to verify the amount of proteins on the 
gel after stripping. For RET/PTC3 anti-RET immunocomplexes (Ip) or 
whole cell lysates (WCL, not shown) were also analysed for RET 
phosphorylation and expression. (C) The effects of other tyrosine 
kinase inhibitors were also analysed. Anti-RET immunocomplexes for 
RETC634R expressing cells treated with PPl ( liiM ), PP2 (IjxM), PP3 
(IjiM ), Genistein (lOO^M) or Herbamycin (0 ,l|iM ) for 12 hours were
separated on reducing 7% SDS-PAGE and transferred to nitro­
cellulose membranes. Upon incubation with anti-pTyr antibodies,
tyrosine-phosphorylated proteins were detected by western blotting. 
After stripping, the amount of protein was verified by re-probing the 
same blots with anti-RET. (D ) TT-cells (a human MTC cell line) were 
immunoprecipitated with anti-RET and western blot analysis with 
anti-RET and anti-pTyr was performed. Equal protein loading was 
confirmed by western blotting on the same TT-cell extracts.
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Consistent with a progressive loss of RET expression upon PPl 
treatment, immunofluorescence analysis of expressing cells
stained for RET showed that the cellular distribution of the receptor 
changed during the period of observation. In fact, whereas in 
untreated cells RET localised both to the cell surface and to 
intracellular compartments, in PPl treated cells, staining with specific 
RET antibodies detected the presence of the mutant receptor mainly 
in intracellular compartments with RET signal particularly intense in 
perinuclear regions around the nuclear membrane but largely absent 
from the cell surface (Fig. 5F). This is particularly evident after 12 
hours of PPl treatment, when RET is still expressed, even though 
western blot analysis shows a consistent decrease in the amount of 
protein (Fig. 5A). Consistent with this, staining cells with anti-RET 
and anti-clathrin antibodies indicated that RET co-localized with 
clathrin after 20 minutes of PPl treatment, indicating that PPl 
stimulated receptor translocation from the membrane to intracellular 
clathrin positive structures (Fig 5F bottom panel). This relocalization 
could be also observed even when immunofluorescence analysis for 
RET was performed on ret ^^ ^®^  and RET/PTC3 transfected cells 
treated with PPl (data not shown). This could indicate that PPl 
induces a progressive aggregation of RET molecules into large 
clusters with a relocalisation to vesicular compartments inside the
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cell. During extended PPl treatments, RET staining tended to 
disappear progressively, also from the perinuclear region, until no 
RET staining could be detected (data not shown).
B X :iC i6 3 4 R + S F l
KETCIS34R.+SP1 2 0
Fig 5: (E) PPl induces RET redistribution in RETC634R expressing cells. 
Where indicated, the transfected cells were plated in the presence of 
1 \iM PPl and after 20 minutes from plating, fixed and double-stained 
with RET (green) and clathrin (red) antibodies. The yellow staining in 
the merged images indicates co-localization of RET and clathrin after
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PPl treatment (details in the insert). Images were analysed using 
confocal microsccopy. Insert: 4x magnification of normal image; bar: 
15 [im.
In order to highlight any significant defect in RET oncoprotein 
biosynthesis in the presence of PPl, we followed the fate of 
metabolically labelled mutant RET receptors expressed in NIH3T3 
cells. Sub-confluent cultures were labelled with ®®S-methionine- 
cysteine for 20 minutes and subsequently chased for varying times. 
Cells were previously grown for 12 hours in the presence or absence 
of PPl and then metabolic pulse-chase experiments performed as for 
untreated cells. As already demonstrated by Bongarzone et al. 
(Bongarzone et al 1999), the amount of and ret ^^ ^®^
increased significantly within the first hour of the chase. In PPl 
treated cells, the fate of both and ret^^ ^®^  receptors was
comparable to that found in untreated cells during the period of 
observation, indicating that PPl did not affect protein biosynthesis 
(data not shown).
4.6 PPl cvtostatic effect on RETC634R and RETM918T expressing 
cells
We examined the cellular proliferation patterns of RET^ ®®'^ ^
and RET/PTC3 expressing cells In the presence or absence of the
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inhibitor. One micromolar PPl exerted a remarkable inhibitory effect 
on the growth of RET/PTC3- expressing cells,
as already demonstrated by Carlomagno et al. (Carlomagno et al, 
2002). Notably, we observed that this cytostatic effect only started 
after 48 hours. In fact RET expressing cells resembled parental cells 
for the first 2 days, but at later times, no increase in the number of 
live cells in the presence of PPl could be detected (Fig. 6). This is 
consistent with the fact that after 48 hours following the addition of 
PPl addition, cells had almost completely lost the expression of the 
RET oncoprotein, suggesting that RET depletion induces growth 
arrest. No apoptotic effect was observed, as demonstrated by TUN EL 
analysis, when performed on cells treated with PPl or PP2 (data not 
shown). This result was confirmed by western blot analysis using 
anti-PARP antibodies, performed on whole cell extracts from cells 
treated with PPl or PP2 for various times. In fact, no cleavage of 
PARP, which facilitates cellular disassembly and serves as a marker 
of cells undergoing apoptosis, was detected (data not shown). The 
proliferation rate of parental and TRKA overexpressing NIH3T3 cells 
was only partially slowed in the presence of PPl (Fig. 5).
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Fig 6: PPl causes growth inhibition o f and
expressing ceiis. Proliferation of cells grown in the presence of PPl 
was assessed. Fifty thousand cells of the indicated cell lines were 
plated and incubated in medium containing or not 1 jiM PPl. Hour 0 
was the treatment starting time. After the indicated period of time, 
cells were counted and the results plotted on a graph. Data are the 
mean of three different experiments.
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4.7 PPl treatment induces ubiauitinated RET oncoproteins 
degradation via oroteosomal targeting
We examined whether the PPl inhibitor could induce RET 
degradation. Incubation of NIH3T3 fibroblasts expressing 
and ret '^ ^^ ®^  receptors with both PPl and the proteosome inhibitor, 
lactacystin, abolished RET destruction as shown by western blot 
detection of RET using an anti-RET specific antibody (Fig. 7A). 
Lactacystin alone did not significantly modify the amount of RET 
protein. RET degradation was also substantially reduced upon 
incubating cells with another proteosome inhibitor, MG132 (data not 
shown). Moreover, RET tyrosine-phosphorylated proteins were 
detected by western blotting with antl-pTyr antibodies (Fig. 7A). The 
bands corresponding to RET mutants were not phosphorylated upon 
treatment with both PPl and lactacystin, again confirming that PPl 
exerts its effect by reducing RET phosphorylation, but that the 
proteosomal inhibition prevented the destruction of 
unphosphorylated protein. Taken together, these results strongly 
indicate that PPl-induced RET degradation is due to proteosomal 
targeting as the inhibition of the proteosome substantially attenuates 
the decrease in RET protein levels. Consistent with these 
observations, chloroquine, a weak base that alkalinises the lysosome, 
was ineffective in inhibiting RET degradation (Fig. 7A), thus
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confirming that PPl treatment most probably targets RET 
oncoproteins to proteosomal, rather than lysosomal, degradation. 
Treatment of the cells with only chloroquine had no effect on RET 
expression (Fig. 7A). Moreover, neither lactacystin nor chloroquine 
displayed any detectable effect on TRK expression as detected by 
western blotting. On the contrary, consistent with previous data 
(Lon g va et al, 2002), chloroquine and to a lesser extent also 
lactaystin, inhibited EGF-mediated degradation of the EGFR in MDA- 
MB-231 cells, shown by western blotting experiments (Fig. 7A lower 
panel).
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Fig 7: PPl induces proteosomai rather than iysosomal degradation o f 
ubiquitinated RET oncoproteins which are bound to Cbi. (A ) NIH3T3 
fibroblasts expressing and receptors were treated
with PPl (l{iM  for 12 hours), with PPl (l|xM for 12 hours) and
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lactacystin (2 |iM for 12 hours) together or with lactacystin (2 jiM for 
12 hours) alone. Cell extracts were immunoprecipitated with anti-RET 
antibodies. Upon incubation with anti-RET antibodies and anti-pTyr 
antibodies, RET proteins and tyrosine-phosphorylated proteins were 
detected by western blotting. Proteins were also extracted from 
RETC634R and expressing cells treated with PPl (IjxM for 12
hours), with PPl (l|iM  for 12 hours) and chloroquine (100 |iM for 12 
hours) together, or with chloroquine (100 |iM for 12 hours) alone. 
Western blot analysis of anti-RET immunoprecipited receptors with 
anti-RET antibody is shown. To assess the effects of proteosomal and 
lysosomal inhibitors on EGF-induced degradation, MDA-MB-231 cells 
were stimulated with EGF (20ng/ml) alone for the indicated time 
periods or with EGF (20ng/ml) together with lactacystin (2 |iM) for 4 
hours or EGF (20ng/ml) and chloroquine (100 |iM) for 3 hours. Whole 
cell lysates were subjected to western blotting using an anti-EGFR 
antibody.
Since no previous data exist regarding the physiological down- 
regulation of RET, interaction with the ubiquitin ligase c-Cbl was also 
investigated. To assess if c-Cbl could also have a role in RET 
oncoprotein degradation and whether PPl treatment could modify 
RET oncoprotein ability to interact with this ubiquitin ligase, western 
blot analysis of anti-Cbl Immunoprecipltates with anti-RET antibodies 
from cells treated or untreated with PPl Indicated that and
RET|^ 918t oncoproteins could associate with c-Cbl (Fig. 7B). Moreover, 
c-Cbl binds to RET oncoproteins irrespective of PPl treatment and of
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RET phosphorylation status. Western blot analysis of both anti-Cbl 
inn mu noprecipitates with anti-RET antibodies (Fig. 7B upper panel) 
and anti-RET immunoprecipltates with anti-Cbl (Fig. 7B lower panel) 
in treated or untreated cells demonstrated that RET and c-Cbl can 
associate in vivo, suggesting that c-Cbl interaction with activated RET 
is an early event not affected by PPl. C-Cbl phosphorylation was also 
studied in untreated cells and cells treated with PPl. Western blot 
analysis of c-Cbl immunoprecitates showed that PPl does not affect 
c-Cbl phosphorylation status (Fig. 6B upper panel), but as already 
demonstrated, dramatically decreased RET phosphorylation and RET 
protein levels in and re t^ ^ is t transfected cells (Fig. 7B lower
panel). In NIH3T3 untransfected cells, c-Cbl phosphorylation was 
nearly undetectable and did not change upon PPl treatment.
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Fig 7: (B) Proteins were extracted from NIH3T3 fibroblasts 
expressing and ret'^^is t receptors treated with PPl (l^M  for
6 and 12 hours as indicated) and c-Cbl immunoprecipltates were 
subjected to western blot analysis with anti-RET, anti-pTyr and anti- 
Cbl antibodies to detect RET expression, RET phosphorylation status.
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c-Cbl expression and phosphorylation in anti-Cbl immunoprecipltates. 
To confirm the results, complementary experiments were performed 
by immunoprecipitating with anti-RET. Anti-RET immunoprecipltates 
(lower panel) were subjected to western blot analysis with anti-RET, 
anti-pTyr and anti-Cbl antibodies to detect RET expression, RET 
phosphorylation, c-Cbl expression and phosphorylation in anti-RET 
immunoprecipltates Proteins were also extracted from untrasfected 
NIH3T3 fibroblasts treated with PPl (l^iM for 6 and 12 hours as 
indicated) and c-Cbl immunoprecipltates were subjected to western 
blot analysis with anti-Cbl and anti-pTyr antibodies to detect c-Cbl 
expression and phosphorylation in anti-Cbl immunoprecipltates.
Ubiquitination of RET mutants was then studied. Western blot 
analysis of anti-RET immunoprecipitated receptors, either treated or 
untreated with PPl and lactacystin, with a monoclonal antibody 
against poly-Ubiquitin, indicated that ret ®^34r g^d RET^^ist 
oncoproteins were ubiquitinated. Since proteosome inhibition leads to 
a depletion of free ubiquitin (Patnalk et al, 2000, Schubert et al., 
2000, Strack et al., 2000), the signal corresponding to ubiquitinated 
RETC634R oncoproteins was more intense when cells were cultured in 
the presence of lactacystin, although ubiquitinated RET could also be 
seen for RET^ ®^ "^  ^ cells treated with PPl alone (Fig. 8A). The same 
results were obtained when analysing the ubiquitination pattern of
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RET'^ 918t oncoproteins (data not shown). Additional 
i mmu noflorescence studies were performed to confirm that the 
RETC634R oncoproteins could be ubiquitinated. REf"®34R expressing 
cells were double-stained with anti-RET polyclonal antibodies and 
monoclonal anti-polyubiquitin antibodies (FK l) to detect 
ubiquitinated RET mutants. Even in these studies, ubiquitinated 
RETC634R oncoproteins could be observed in untreated cells (Fig. 8B 
upper panel and details in Fig. 8B) as well as in PPl treated cells 
(Fig. 8B lower panel), thus suggesting that PPl did not promote 
ubiquitination. Thus, RET oncoproteins are constitutively 
ubiquitinated and PPl treatment does not induce neither affect 
protein ubiquitination. Taken together, these findings indicate that 
RET oncoproteins can bind to c-Cbl, can be ubiquitinated and 
therefore targeted to proteasomal degradation irrespective of PPl 
treatment. However, proteosomal degradation is strongly accelerated 
when cells are treated with PPl.
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Fig 8: RET oncoproteins are constitutively ubiquitinated even in the 
absence o f PPl (A) NIH3T3 fibroblasts expressing receptors
were treated with PPl (IjxM for 12 hours) or PPl (l|iM  for 12 hours) 
and lactacystin (2|xM for 12 hours) or lactacystin alone (2|xM for 12 
hours). Cell extracts were immunoprecipitated with anti-RET 
antibodies. Upon incubation with anti-Ubiqultin monoclonal
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antibodies, anti-RET antibodies and anti-pTyr antibodies, poly- 
ubiquitinated RET proteins, RET proteins and tyrosine-phosphorylated 
proteins were detected by western blotting. (B) NIH3T3 fibroblasts 
expressing RET^ ®®^ ® receptors, were plated in the absence (upper 
panels) or in the presence of 1 |iM PPl (lower panel) and, after 12 
hours from plating, fixed and double-stained with anti-RET that was 
detected by using a rhodamine-conjugated secondary antibody (red) 
and anti-polyubiquitin monoclonal antibodies that were detected by 
using a FITC-conjugated secondary antibody (green) and subjected 
to confocal analysis. Areas of overlap between RET and poly-ubiquitin 
appear in yellow. The arrows in the upper panel show interesting 
details reported below at a higher magnifictation to better illustrate 
the colocalisation of RET and Ubiquitin. Images were analysed using 
confocal microsccopy. Bar: 15 |im.
4.8 Discussion
In recent years, several efforts have been made to develop 
therapeutic strategies targeting oncoproteins. Cancer therapy 
directed to specific molecular alterations In the signalling pathways of 
cancer cells has been validated especially for the treatment of 
advanced breast cancer and gastrointestinal stromal tumors. For 
ErbB proteins, a group of drugs are already in the advanced stages of 
clinical testing (Levitzki, 1999; Fry, 2000). These tyrosine kinase 
inhibitors are very selective, and as a consequence of blocking the
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kinase activity most of the down stream signalling pathways are 
inhibited, leading to growth arrest of tumors dependent on ErbB 
signalling induced proliferation.
I t  would be of great interest to identify inhibitors for RET 
tyrosine kinase in order to develop new therapeutic strategies for 
RET associated diseases and in particular for medullary thyroid 
carcinoma, which is the common clinical manifestation of MEN 2 
syndromes. MTC responds very poorly to chemotherapy and at 
present, the only cure involves a total thyroidectomy. Recently, 
Carlomagno et al. have suggested that PPl could be used in order to 
inhibit RET/PTC induced tumorigenesis (Carlomagno et al, 2002).
A key finding made during the course of this present study, 
which was aimed to discover the effects of PPl on and
l^gjM9i8T expressing cells, was the unexpected ability of both the two 
related tyrosine kinase inhibitors, PPl and PP2, to induce 
proteosomal destruction of RET oncoproteins. In fact, though PPl 
was shown to inhibit RET oncoprotein kinase activity (our data and 
Carlomagno et al, 2002) and to affect RET/PTC3 dependent MAPK 
phosphorylation as early as 2 hours after exposure (Carlomagno et 
al, 2002), analysis of long-term effects of PPl treatment showed that 
there was a remarkable decrease in the levels of RET oncoproteins 
after 12 hours (Fig. 4A) and a clear reversion of the transformed
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phenotype was observed (Fig. 1). Moreover, cells expressing RET 
oncoproteins treated with PPl proliferated like untreated cells for the 
first two days after PPl addition but at later times, a clear cytostatic 
effect was detectable (Fig. 5) and no RET oncoprotein expression was 
found (Fig. 4A). Therefore, our observations extend on previous 
reports stating a linkage between the inhibition of RET 
phosphorylation and cell growth (Carlomagno et al, 2002), and 
suggest that drug-induced receptor destruction clearly contributes to 
the cytostatic effect of tyrosine kinase inhibitors. Moreover, it is 
tempting to speculate that a stable phenotypical reversion of RET 
transformed cells and growth arrest might be due to the initial 
dephosphorylation of RET and its consequent depletion.
No studies have been performed to elucidate the way the RET 
receptor is physiologically degraded in cells and no data are available 
on the down regulation of the constitutively activated receptor. For 
ErbB proteins, two major inducible pathways that control their 
degradation have been well highlighted: ligand-induced rapid
endocytosis of ErbB-1 (Levkowitz et al, 1999), and antibody- and 
oncogenic mutation-induced destruction of ErbB-2 (Levkowitz et al, 
2000), pathways that are both mediated, at least in part, by the c- 
Cbl ubiquitin ligase. Cbl proteins have a key role in sorting active 
receptor tyrosine kinases (RTKs) into invaginating pits and function
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as ubiquitin protein ligases that direct multi-ubiquitination and 
downregulation of RTKs. Cbl-mediated ubiquitination accelerates 
EGFR endocytosis and its delivery to lysosomes for degradation 
(Levkowitz et al, 1999). Thus, the sorting of RTKs to be internalized, 
is controlled by two types of reversible modification, phosphorylation 
and ubiquitination.
The RET mutants associated with MEN2A and MEN2B utilised in 
this study are constitutively activated and therefore constitutively 
phosphorylated. Unexpectedly, consistent with this constitutive 
phosphorylation status of RET oncoproteins, we reported that a high 
proportion of these oncogenic proteins are ubiquitinated and 
associate with c-Cbl and ubiquitin. Moreover, treatment of the cells 
with PPl does neither promote nor modify this interaction, although 
the inhibitor abolishes RET oncoprotein phosphorylation but not c-Cbl 
phosphorylation status. The binding of c-Cbl to RET which had yet to 
be demonstrated, has now been shown to be an early event for these 
oncogenic products and that is not affected by PPl-mediated RET 
dephosphorylation. None of the RET tyrosine residues phosphorylated 
and/or relevant for RET-mediated mitogenesis seemed to be directly 
involved in binding c-Cbl, although substitutions of specific tyrosine 
residues in the intracellular domain of RET have been performed 
(data not shown). Therefore, the ability of RET to bind c-Cbl can be
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separated from its ability to drive mitogenic signalling. Consistent 
with this, the use of the PPl inhibitor does not change the ability of 
c-Cbl to interact with RET, since probably none of the RET tyrosine 
residues whose phosphorylation is impaired by the inhibitor, are 
involved in c-Cbl binding. PPl might then have a role in inhibiting the 
RET mitogenic signalling cascade but not the pathways that control 
its degradation. Taken together, our results also give rise to 
intriguing questions on how the fate of RET oncoproteins is 
determined since their phosphorylation is constitutive, as is their 
binding to c-Cbl and their ubiquitination.
Interestingly, Citri et al. (Citri et al, 2002) indicated that the 
tyrosine kinase inhibitor CI-1033, directed ErbB-2 to a degradative 
fate mediated by the chaperone destructive system, which is 
functionally and structurally distinct from the c-Cbl-mediated 
pathway (Citri et al, 2002). The Cbl-mediated pathway requires 
kinase activity to induce degradation whereas the chaperone- 
mediated route is recruited to the kinase domain mainly upon a 
structural perturbation of the ATP-binding pocket of the oncoprotein. 
PPl could act on RET oncoproteins through the activation of similar 
pathways and the hypothesis that PPl could target the receptor to 
destruction by inducing such a structural perturbation, thus recruiting 
the stress-inducible machinery, is under current study.
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In conclusion, we have shown here that the previously reported 
results on PPl activity on cytoplasmic RET fusion proteins can be 
convincingly extended to both membrane-bound RET mutants 
associated with MEN2A and MEN2B syndromes and to sporadic 
medullary thyroid carcinomas, emphasizing the potential therapeutic 
role of this compound. In fact, after PPl mediated 
dephosphorylation, RET oncoproteins are rapidly targeted to 
proteosomal destruction. Interaction with the inhibitor can therefore 
either block most of the downstream mitogenic signalling, apart from 
the one driven by c-Cbl so that recycling is prevented and 
invagination and degradation accelerated, or it can mis-fold the 
protein structure which is then targeted to stress-induced rapid 
destruction.
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5. CONSTRUCTION AND ANALYSIS OF retC62QR HOMOZYGOUS 
MICE
5.1 Introduction
The c-Ret proto-oncogene encodes a receptor tyrosine kinase 
(RTK) that is expressed widely in mammalian embryos and has 
diverse roles in development and disease (Takahashi et al, 1985, 
1988; Taraviras and Pachnis 1999; Baloh et al. 2000; Jhiang 2000). 
During embryogenesis, the main sites of c-Ret expression are the 
excretory and nervous systems (Pachnis et al. 1993; Tsuzuki et al.
1995). In the nervous system, c-Ret is expressed in the progenitors 
of the enteric nervous system (ENS), in enteric, autonomic, and 
sensory neurons of the peripheral nervous system (PNS), and in 
motor and catecholaminergic neurons of the central nervous system 
(CNS). The majority of enteric neurons and glia are derived from a 
subset of neural crest (NC) cells that emigrate from the neural tube 
at the level of somites 1-7. On invading the foregut mesenchyme, 
enteric NC (ENC) cells migrate in a rostrocaudal direction and 
colonize the wall of the gastrointestinal tract (Kapur et al. 1992; 
Durbec et al. 1996). Mutations of c-RET in humans lead to absence 
of enteric ganglia from the distal colon and congenital megacolon
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(Hirschsprung's disease, HSCR; Parisi and Kapur 2000), whereas 
R e tk - /R e tk -  mice lack all enteric ganglia posterior to the stomach 
(intestinal aganglionosis; Schuchardt et al. 1994; Durbec et al.
1996). Although some of the cellular processes controlled by RET 
(such as survival, migration, and differentiation of ENC) have been 
identified, the mechanisms that lead to the localized absence of 
enteric ganglia in HSCR patients remain unclear. Gain-of-function 
mutations of c-Ret have also been described in humans and 
reproduced in mice by targeted mutagenesis. These mutations 
result in the constitutive activation of RET and are associated with 
multiple endocrine neoplasia (MEN) types 2A and 2B and familial 
medullary thyroid carcinoma (FMTC), inherited cancer syndromes 
characterized by tumors of neuroendocrine origin (Jhiang 2000; 
Smith-Hicks et al. 2000). Although MEN 2 mutant forms of the RET 
protein efficiently transform fibroblasts (our results), the ir biological 
effects in mice have remained elusive and until now, no model 
mimicking the co-occurrence of HSCR and MEN2A was available.
I have targeted the mouse RET locus by homologous 
recombination to generate a strain of mice that carries the C620R 
RET mutation in order to study the role of the mutation in
vivo and hopefully have the first mouse model which could be 
studied in terms of tumor development and developmental
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disorders such as HSCR disease. Heterozygous mice are viable. In 
contrast, homozygous mice expressing the mutation die
early after birth and lack kidneys. This is in line with previous 
findings showing that mice homozygous for a targeted mutation of 
c-Ret ( R e tk - )  have severe hypodysplasia or aplasia of the kidneys 
(Schuchardt et al. 1994, 1996; Durbec et al. 1996; Srinivas et al. 
1999) and die within 24 hours after birth. The excretory system of 
knockout RET mice exhibited a wide spectrum of abnormalities 
ranging in severity from bilateral or unilateral renal agenesis, 
blind-ending ureters with no renal tissue, to small and dysplastic 
kidney rudiments. The mammalian kidney is generated by reciprocal 
inductive interactions between the ureteric bud and the 
undifferentiated metanephric mesenchyme. Whereas the 
mesenchyme is important for the growth and branching of the UB, 
which gives rise to the renal collecting system, the tips of the UB 
branches induce the surrounding mesenchymal cells to condense 
into epithelial vesicles, which differentiate into the various segments 
of the nephrons (Saxen and Sariola, 1987). In mice, c-Ret mRNA is 
first detected in the nephric duct of the pronephros and 
mesonephros at E8.5-E10.5, with the highest levels at the caudal 
end of the duct, from which the ureteric bud later evaginates. At 
E l l . 5, when the UB has branched within the metanephric
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mesenchyme, c-Ret is expressed throughout the ureteric bud and 
its function is necessary for évagination, growth, and branching of 
this structure (Pachnis et al. 1993; Schuchardt et al. 1994, 1996; 
Sainio et al. 1997; Ehrenfels et al. 1999; SchedI and Hastie 2000).
5.2 Construction of the Transaene
In order to target the mouse RET locus by homologous 
recombination in embryonic stem (ES) cells, we first isolated a ret 
genomic clone by screening a mouse 129 lambda bacteriophage 
DNA library (129/Sv) using RET cDNA containing exon 10 as a 
probe. The targeting vector, was constructed using a a 1.8kb 5' 
BamHI-BamHI fragment and a contiguous 4kb BamHI-SacI 3' 
fragment containing exons 10 and 11 in pBluescript SK (Strtagene) 
followed by site-directed mutagenesis using the QuickChange kit 
(Stratagene) and PAGE-purified mutagenic primers. The pGKneoTK 
selection cassette (a gift from T.H. Rabbits), flanked by loxP sites to 
allow its removal by the Cre recombinase was inserted into the 
Bglll site immediately downstream of exon 11. The diphtheria toxin 
A chain gene contained within the pKOselectDT plasmid (Stratgene; 
Greenfield et al. 1983, GenBank Acc. # K01722) was inserted into 
the 5' RsrII site, such that it was outside the 5' region of homology
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(F ig .l). The targeting construct was linearised with Notl and 
electroporated into CCB ES cells (a gift from MJ. Evans) derived 
from the 129S7 strain. ES cells were plated on mitomycin C-treated 
primary embryo feeder cells grown on gelatin and obtained from a 
Rosa26 X MFl cross (and therefore G418-resistant) followed by 
selection in G418.
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F ig  1
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Fig. 1 The targeting the murine locus: A. "Touch and go"
homologous recombination for Ret '"knock-in". The targeting vector 
was constructed using a a l.Skb 5' BamHI-BamHI fragment and 
contiguous 4kb BamHI-SacI 3' fragment containing exons 10 and 
11 followed by site-directed mutagenesis. The pGKneoTK selection 
cassette flanked by loxP sites to allow its removal by the Cre 
recombinase, was inserted into the Bglll site immediately 
downstream of exon 11. The diphtheria toxin A chain gene 
contained within the pKOselectDT plasmid was inserted into the 5' 
RsrII site such that it was outside the 5' region of homology. The 
targeting construct was linearised with Notl. B. Details o f the 
construction o f the targeting vector pBS Bam RetC620R.
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Of 197 G418-resistant clones, 8 (4%) had the targeted insertion 
according to the applied PCR screening method (P I, 5'- 
aagctctctagtcgaggaat-3' and P2, 5'-ggcctctgaaggactgaa-3') (Fig 
2A). Southern blotting confirmed that 4 of these had the targeted 
allele of the expected size (Fig 2B). DNA sequencing confirmed 
that 2 clones (1%) had the C620R RET mutation (not shown). The 
floxed selection cassette was excised in vitro in the RET C620R- 
neoTK/+ ES using pCre-Pac (a g ift from D.J. Winton). Of 161 
clones, 11 had undergone cre-mediated excision of the selection 
cassette as shown by PCR analysis performed on the DNA of the 
ES cell clones (Fig 2C). Only 2 clones were confirmed positive 
when sequencing analysis was performed (data not shown). One 
targeted ret C620R/+ ES cell clone was expanded and 
microinjected into C57B1/6J blastocysts at the Gene Targeting 
Facility, Babraham Institute, Cambridge, to obtain chimaeric mice. 
Of 146 live-born pups, this clone gave rise to 18 highly chimaeric 
animals in which the percentage chimaerism was exceptionally 
good (1x100%, 7x90%, 8x80%, 1x70%,1x50%). The chimaera 
with the greatest ES cell contribution was chosen and used to 
transmitt the mutation through the germline to 4 of 8 pups. The 
genotypes of these animals were confirmed using a two-primer 
assay (P I, 5'-tgccgacattgttggaggaac-3' and P2, 5'-
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cctggctgttcctctggct-3'). A 120 base-pair bp amplification product is 
generated from the wild-type allele which is not cleaved after 
digestion with the restriction enzyme BSTUI that instead, gives a 
98bp fragment for the allele bearing the C620R substitution. 
Animals were bred to C57BL/6J mice to generation N3 before 
intercrossing and therefore segregate C57BL/NJ and 1295/ alleles 
in the ratio of 6:1, respectively. The official nomenclature for this 
mouse line is, C57BL/6JN3TgH(ret620)Ac620, which has been 
abbreviated to B6N3Ac620 and hereafter referred to as retC620R.
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Fig. 2 Detection o f homologous recombination events in the ES 
clones. A. DNA was extracted from the 197 G418-resistant ES cell 
clones, 8 (4%) had the targeted insertion according to the PCR 
screening method (P I, 5'-aagctctctagtcgaggaat-3' and P2, 5'- 
ggcctctgaaggactgaa-3') which amplifies a 2kb fragment in the 8 
targeted clones (blue arrows) and a 1.5 Kb fragment in the wild 
type (red arrow) and in the non targeted clones. B. Southern 
blotting confirmed that 4 of the above 8 clones had the targeted
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allele of the expected size of 8kb (blue arrows) compared to the 
wild type size of 5kb (red arrow). The DNA was digested with 
BamHI and hybridized to a probe obtained by amplifying a 
fragment containing ret exon 11 and therefore present in both the 
targeted and non-targeted clones (P I, 5'-acagggggaggtggtacagt- 
3' and P2, 5'-atgccgtatccaccatctgt-3')- C. PCR-based analysis of 
the clones after the electroporation of the Cre-recombinase. Of 
161 clones, 11 had undergone cre-mediated excision of the 
selection cassette and displayed the correct expected size (blue 
arrows) after DNA amplification through the region of the insertion 
of the cassette as a loxP site remains and gives a band of 
approximately 500bp compared to the wild type (red arrow) and 
the non targeted that are shorter (450bp) (P I, 5'- 
cagggcttcccaatcagtt-3' and P2, 5'-ccgagtacatgtgtgcctgt-3')- D. 
PCR-based analysis of representative tail biopsies from a litter of 
pups of one heterozygous breeding pair. A 120 base-pair bp 
amplification product (P I, 5'-tgccgacattgttggaggaac-3' and P2, 5'- 
cctggctgttcctctggct-3') is generated from the wild-type allele 
which is not cleaved after digestion with the restriction enzyme 
BSTUI that instead, gives a 98bp fragment for the allele bearing 
the C620R substitution. The products of the amplification and 
digestion of control wild type DNA (red arrow) and DNA from the 
targeted retC620R vector (blue arrow) are loaded on the gel as 
controls. The resulting genotype of each pup is indicated. - /-  Wild 
type; + /- heterozygous; + /+  homozygous mutant.
155
retCôZOR homozygous mice
5.3 retC620R homozvaous mice die early postnataHv
All heterozygous retC620R mice appeared healthy and grew 
and reproduced normally. The genotype distribution of the 
new-born mice obtained from retC620R^^" intercrosses was as 
follows: wild type 24%; heterozygous 51% and homozygous 
25%, indicating that there was no significant increase in 
embryonic lethality of homozygous retC620R mice. At birth, 
homozygous mutants were the same size as their wild-type 
and heterozygous littermates, responded to tail pinch, and 
nursed normally. However, all retC620R homozygous mice, 
died within 24 hours of birth. The mice were all analyzed for 
the inheritance of the retC620R transgene through the 
extraction of genomic DNA from tail samples collected from all 
the littermates.
5.4 Enteric Nervous System Deficits and Kidnev agenesis in 
retC620R homozvaous mice
Dissection of newborn homozygous retC620R mice 
revealed that many of them had milk in the esophagus (which 
was not observed in wild-type animals) and little milk beyond 
the proximal small bowel, suggesting defects in gastrointestinal 
peristalsis. Given the absence of enteric neurons beyond the
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Stomach in Ret-, GDNF- and GFRalphal- deficient animals, it 
seemed likely that these observations similarly reflected 
defects in the enteric nervous system of our mice. Microscopic 
analysis and immunohistochemistry, with antibodies specific for 
neuron-specific enolase (NSE) demonstrated that enteric 
ganglion cells were absent in the esophagus, stomach, in the 
small or large bowel of retC620R animals (Fig.3) but they were 
present in both the wild type and heterozygous mice.
w',-r
Colon wt NSE lOX Colon RetC62DR NSE IGOC
Smal intestine wt NSE lOX Smal intestine RetC620R NSE lOX
Stomach wt NSE lOX Stomach RetC620R NSE lOX
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Fig. 3 Histological Analysis of the Enteric Nervous System in 
RetC620R mice: Neuron-specific enolase (NSE) staining
demonstrates readily identified ganglion cells in the wall of the 
Intestine and stomach jus t in wild type animals whereas in 
RetC620R mice no staining is present.
Moreover, it was found that the homozygous newborn 
animals had agenesis of the kidneys as well as empty bladders 
(Fig. 4). All of them lacked both kidneys, consistent with what 
was observed for mice lacking Ret, GDNF or GFRalphal. Renal 
abnormalities in heterozygous retC620R mice was searched for, 
but all of the mice examined had two kidneys, 
undistinguishable from those in the wild-type animals. This is 
similar to what was reported for both Ret+/- mice (Schuchardt 
et al., 1994) and GFRalphal’^ ''" mice (Enomoto et al., 1998), 
but in sharp contrast to what was observed in GDNF^^" mice 
where up to 30% of heterozygotes displayed kidney 
abnormalities (Sanchez et al., 1996).
The adrenal glands and components of the urogenital system 
including the testes, vas deferens, ovaries, oviducts and uteri, 
appeared macroscopically normal.
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Fig. 4 Kidney agenesis in retC620rR mouse. No renal tissue 
could be observed in retC620R homozygous mice even when all 
the organs hiding the kidneys were removed for a clear 
observation. The wild type and heterozygous mice had normal 
urogenital systems. Hematoxylin/Eosin sections are shown in 
the lower panel.
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5.5 Discussion
Previous studies have established the absolute requirement of 
GDNF, RET and GFRalphal in the development of the enteric 
nervous system and kidneys. I have shown here that mice 
homozygous for retC620R lack kidneys and have defects in the 
enteric nervous system, as do knock-out mice for GDNF, RET 
and GFRalphal. In fact, these events lead to the death of all 
the ret620R homozygous animals as is the case in RET, GDNF 
and GRFalphal knockouts. These results indicate that the RET 
mutant we introduced completely impaired the development of 
the affected organs and thus the signals triggered by the RET, 
GDNF and GFRalphal complex are impaired.
I have already shown in the previous chapters of this 
thesis, through the biochemical analysis of the transfected RET 
mutants in NIH3T3 cells, that the RETC620R protein hardly 
translocate to the cell membrane. Most of it was retained in the 
endoplasmic reticulum where the mutated protein could not 
interact with either GDNF or GFRalphal and thus trigger the 
signals necessary for the development of the kidneys. I t  was 
also shown that the RETC620R mutants did not respond to 
GDNF, since SK-N-MC cells did not scatter when ligand is 
added.
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Although very preliminary, these results strengthen the 
idea, which was already proposed during the course of this 
study, suggesting that the reason why the RETC620R mutation 
is concomitantly associated with both the MEN2A syndrome 
and HSCR disease relies on the fact that for an efficient 
development of both the kidney and the enteric nervous 
system, RET needs to be present at the cell surface signaling 
through the interaction with GDNF and its coreceptor. On the 
other hand, as well demonstrated biochemically in this thesis, 
RET can signal even from the endoplasmic reticulum where the 
RETC620R mutant is retained and bind to the mitogenic 
components of the cascade essential to drive mitogenesis. In 
humans in fact, this mutations never occurs in homozygosis 
since probably no individuals would survive due to the severe 
defects that the lack of at least one copy of RET wild type could 
cause.
One of the oldest animals we have now seems to present 
an enlargement of the thyroid, probably indicating the 
presence of a tumor but we have no data on tum or formation 
in these mice as they are jus t 10 months old and we have yet 
to sacrifice any of them. These mice with could be crossed to 
other strains to study whether the same mutation induces
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different phenotypes when inserted in diverse genetic 
backgrounds. A veterinary unit will analyze the histology of the 
homozygous mice which died just after birth, since we are also 
interested in obtaining some more insights into the nervous 
system of these mice and look for other abnormalities similar 
to those found in RET, GDNF and GRFalphal knockouts.
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6. CONCLUSIONS
The overall aim of this work was to investigate the 
expression of different RET mutants in order to highlight their 
biological role in diverse cellular contexts. In particular, this 
thesis focuses on gain of function Cys mutations that are 
responsible for medullary thyroid carcinoma by causing the 
covalent dimerization of RET, leading to ligand-independent 
activation of its tyrosine kinase. In this context, the association 
of Cys®°® and Cys®^ ° activating mutations with HSCR is stiil an 
unresolved paradox. In the attempt to clarify why an activating 
mutation can aiso give rise to the absence of enteric neurons, I 
have produced severai iines of evidence that suggest that the 
mitogenic signaling responsible for growth and development of 
medullary thyroid carcinoma does not require either the 
presence of the RET protein at the ceil surface or the formation 
of the RET/iigand/coreceptor complex. On the other hand, this 
complex is strictly necessary for the correct development of the 
enteric nervous system and the excretory system. Therefore, 
the presence of a functional RET at the cell surface is absolutely 
critical in order to mediate the effects of GDNF during renal and 
enteric nervous system development.
For the first time, mice bearing a single substitution at RET 
codon C620R were generated and represented a very useful
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tool in our study. When these mice were bred to homozygousity 
they died early post nataliy and completely lacked an excretory 
system. There is evidence that suggests that similarities exist 
between these mice and mice lacking either GDNF or RET or 
GRFRal. All three mutant animals show absolute losses of 
enteric ganglion cells in the distal gut (small intestine and 
colon), whereas some enteric neurons remain in the proximal 
gut (stomach and esophagus), characteristics that have been 
aiso found in our mice.
The generated mutant animal could also represent a very 
interesting model in which to study Medullary Thyroid 
Carcinoma development and growth. One of the oldest mice we 
have (10 months old), presents as expected, a macroscopically 
detectable thyroid enlargement that is probably a tumor 
formation. Based on the results of a recent paper by Cranston A 
(Cranston AN and Ponder BA, 2003), I too would like breed 
these animals and introduce the mutation into different genetic 
backgrounds to study any eventual differences in the rate of 
tumor growth in order to identify possible genes that 
predispose for the disease. It was demonstrated that the 
occurrence of tumours in RET transgenic mice depends on the 
genetic background of the host (Cranston AN and Ponder BA, 
2003). Stiii in collaboration with Dr. Cranston, I am trying to 
create a transgenic animal which expresses the proto-
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oncogene with exactly the same procedure applied for the 
generation of the mice. ES cells clones obtained after
electroporation with the plasmid bearing the mutation need to 
be tested for the presence of ret ®^^ "^  ^ and to be used for 
morula aggregation in order to obtain the transgenic animal. 
Future studies will then focus on the differences between the 
retC620R and the retC634R mice.
These animals are possibly a good source of tumor ceil 
lines and good models in which to study how the inhibitor we 
studied and others drugs work in vivo. During the course of this 
study, a new and interesting potential treatment strategy, using 
PPl inhibitor was proposed. This inhibitor, originally described 
as a Src family kinase inhibitor, rapidly affects RETMEN2A and 
RETMEN2B oncoprotein phosphorylation and targets them to 
the degradative pathway. PPl treatment would represent a 
promising new strategy to selectively target RET oncogenic 
products for destruction and could be used to develop new 
therapeutic techniques for Medullary Thyroid Cancer therapy 
whose tumors respond very poorly to chemotherapeutic agents. 
The obtained results are also relevant since no studies have 
been performed to elucidate the way the RET receptor becomes 
physiologically degraded in cells and no data are available on 
the mechanisms controlling the down regulation of 
constitutively activated receptors. They also give rise to
165
Conclusions
intriguing questions on how the fate of RET oncoproteins is 
determined as their phosphorylation is constitutive as is their 
binding to c-Cbl and their ubiquitination.
Further studies will focus on the different pattern of 
protein expression of cells bearing RET proto-oncogenes treated 
or not with the PPl inhibitor. These experiments will be 
performed by two-dimensional electrophoresis approach 
followed by analysis of the expressed proteins using Mass 
Spectrometry. Preliminary results have already indicated 
consistent differences in the "phosphoproteome" of the cell 
lines when treated or not with PPl.
The results obtained, when testing the PPl inhibitor on 
various RET mutants, prompted us to try to re-classify the 
different RET mutation according to their responsiveness to 
PPl: one of the hypothesis we favour In explaining the activity 
of the inhibitor is that the degradative signals recruited to the 
kinase are mainly due to structural perturbation of the ATP- 
binding pocket of the oncoprotein, where PPl might enter and 
physically interact with RET. RET mutants bearing substitutions 
in the ATP-binding domain behave differently when treated with 
PPl with respect to the exact location of the substitution. This is 
the subject of a new article that was submitted for publication 
together with Dr. Cranston A. in collaboration with Dr. Taylor S. 
and her crystallography group.
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In conclusion, this study gives rise to a number of 
interesting issues that need to be further investigated, utilizing 
also the animal model designed for the study of MEN2A and 
MEN2A/HSCR.
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